Header Logo

ROBERT COLEMAN

TitleProfessor
InstitutionMD Anderson
DepartmentGynecological Oncology & Reproductive Medicine
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Sfeir S, Allen L, Algera MD, Morton R, Farrell R, Brennan D, Driel WJV, Rijken MJ, Eiken M, Sundar SS, Coleman RL, collaborators of the Global Equality in Ovarian Cancer Care project group. Exploring global barriers to optimal ovarian cancer care: thematic analysis. Int J Gynecol Cancer. 2024 Sep 02; 34(9):1408-1415. PMID: 38821547.
      Citations:    Fields:    
    2. O'Regan RM, Zhang Y, Fleming GF, Francis PA, Kammler R, Viale G, Dell'Orto P, Lang I, Bellet M, Bonnefoi HR, Tondini C, Villa F, Bernardo A, Ciruelos EM, Neven P, Karlsson P, M?ller B, Jochum W, Zaman K, Martino S, Geyer CE, Jerzak KJ, Davidson NE, Coleman RE, Ingle JN, van Mackelenbergh MT, Loi S, Colleoni M, Schnabel CA, Treuner K, Regan MM. Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. JAMA Oncol. 2024 Aug 15. PMID: 39145953; PMCID: PMC11327904.
      Citations:    Fields:    
    3. Monk BJ, Coleman RL, Tewari KS, Randall LM, Pothuri B, Slomovitz BM, Herzog TJ. Response to Alexandre Andre B A da Costa et al. Gynecol Oncol. 2024 Aug 13; 189:146-147. PMID: 39142061.
      Citations:    Fields:    
    4. How JA, Dang M, Lee S, Fellman B, Westin SN, Sood AK, Fleming ND, Shafer A, Yuan Y, Liu J, Zhao L, Celestino J, Hajek R, Morgan MB, Parra ER, Laberiano Fernandez CD, Arrechedera CA, Solis Soto LM, Schmeler KM, Nick A, Lu KH, Coleman R, Wang L, Jazaeri AA. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med. 2024 Aug 10. PMID: 39151421.
      Citations:    Fields:    
    5. Nemunaitis J, Stanbery L, Walter A, Wallraven G, Nemunaitis A, Horvath S, Bognar E, Rao D, Engle S, Brun S, Ghisoli M, Rocconi RP, Monk BJ, Coleman RL. Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy. Future Oncol. 2024 Aug 05; 1-16. PMID: 39101448.
      Citations:    Fields:    
    6. Coleman RL, Lorusso D, Oaknin A, Cecere SC, Denys H, Colombo N, van Gorp T, Konner JA, Romeo Marin M, Harter P, Murphy C, Wang Y, Esteves B, Method M, Matulonis U. Mirvetuximab soravtansine in folate receptor alpha (FRa)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial. Int J Gynecol Cancer. 2024 Aug 05; 34(8):1119-1125. PMID: 38858103; PMCID: PMC11347190.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    7. Vergote I, Perez Fidalgo A, Valabrega G, Monk BJ, Herzog T, Cibula D, Colombo N, Pothuri B, Sehouli J, Korach J, Barlin J, Papadimitriou CA, van Gorp T, Richardson D, McCarthy M, Antill Y, Mirza MR, Li K, Kalyanapu P, Slomovitz B, Coleman RL. ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug 05; 34(8):1283-1289. PMID: 38627035; PMCID: PMC11347228.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    8. Kim MS, Glassman D, Handley KF, Lankenau Ahumada A, Jennings NB, Bayraktar E, Foster K, Joseph R, Lee S, Coleman RL, Sood AK. Mechanism and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer. Cancer Med. 2024 Aug; 13(15):e70031. PMID: 39114948; PMCID: PMC11306972.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    9. Mirza MR, Chase DM, Slomovitz BM, Christensen RD, Nov?k Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA. A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer". Future Oncol. 2024 Jul 11; 1-18. PMID: 38990090.
      Citations:    Fields:    
    10. Monk BJ, Tewari KS, Randall LM, Pothuri B, Slomovitz BM, Coleman RL, Herzog TJ. Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18. Gynecol Oncol. 2024 Sep; 188:81-82. PMID: 38936284.
      Citations:    Fields:    
    11. Chan JK, Tewari K, Monk BJ, Herzog TJ, Coleman RL, Richardson MT, Kapp DS, Francoeur AA. Biomarker guidance in selection among breakthrough treatment options in advanced and recurrent endometrial cancer. Gynecol Oncol. 2024 08; 187:249-252. PMID: 38838439.
      Citations:    Fields:    Translation:Humans
    12. Pitiyarachchi O, Ansell PJ, Coleman RL, Dinh MH, Holman L, Leath CA, Werner T, DiSilvestro P, Morgan M, Tew W, Lee C, Cunningham M, Newton M, Edraki B, Lim P, Barlin J, Spirtos NM, Tewari KS, Edelson M, Reid T, Carlson J, Friedlander M. Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70?years and over. Gynecol Oncol. 2024 08; 187:221-226. PMID: 38821039.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    13. Ramirez PT, Robledo KP, Frumovitz M, Pareja R, Ribeiro R, Lopez A, Yan X, Isla D, Moretti R, Bernardini MQ, Gebski V, Asher R, Behan V, Coleman RL, Obermair A. LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. J Clin Oncol. 2024 Aug 10; 42(23):2741-2746. PMID: 38810208.
      Citations: 1     Fields:    Translation:Humans
    14. Gien LT, Enserro DM, Block MS, Waggoner S, Duska LR, Wahner-Hendrickson AE, Thaker PH, Backes F, Kidd M, Muller CY, DiSilvestro PA, Covens A, Gershenson DM, Moore KN, Aghajanian C, Coleman RL. Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016. Gynecol Oncol. 2024 07; 186:61-68. PMID: 38603953; PMCID: PMC11265792.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    15. Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, Matulonis U, O'Malley D, Raspagliesi F, Scambia G, Monk BJ. Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer. Int J Gynecol Cancer. 2024 Apr 01; 34(4):469-477. PMID: 38101816.
      Citations:    Fields:    Translation:Humans
    16. Tjokrowidjaja A, Friedlander ML, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, Pujade-Lauraine E, Lord SJ, Scott CL, Goble S, York W, Lee CK, Gynecologic Cancer Intergroup Meta-Analysis Committee. Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor. J Clin Oncol. 2024 Apr 10; 42(11):1301-1310. PMID: 38215359.
      Citations: 1     Fields:    Translation:Humans
    17. Rugo HS, Van Poznak CH, Neven P, Danielewicz I, Lee SC, Campone M, Chik JYK, Vega Alonso E, Naume B, Brain E, Siegel JM, Li R, Uema D, Wagner VJ, Coleman RE. Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials. Breast Cancer Res Treat. 2024 Apr; 204(2):249-259. PMID: 38123789; PMCID: PMC10948526.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    18. Nemunaitis J, Stanbery L, Willoughby D, Bognar E, Brun S, Walter A, Monk BJ, Rocconi RP, Choucair K, Coleman RL. Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy Response. Cancers (Basel). 2023 Nov 28; 15(23). PMID: 38067319; PMCID: PMC10705148.
      Citations:    
    19. Velikova G, Morden JP, Haviland JS, Emery C, Barrett-Lee P, Earl H, Bloomfield D, Brunt AM, Canney P, Coleman R, Verrill M, Wardley A, Bertelli G, Ellis P, Stein R, Bliss JM, Cameron D, TACT2 Trial Management Group. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2023 12; 24(12):1359-1374. PMID: 37926100.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    20. Coleman RL, Garside J, Hurteau J, Nguyen J, Kobayashi M. Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States. J Health Econ Outcomes Res. 2023; 10(2):82-90. PMID: 37905183; PMCID: PMC10613433.
      Citations: 2     
    21. Randall LM, O'Malley DM, Monk BJ, Coleman RL, Gaillard S, Adams S, Duska LR, Dalton H, Holloway RW, Huang M, Chon HS, Cloven NG, ElNaggar AC, O'Cearbhaill RE, Waggoner S, Tarkar A, Striha A, Nelsen LM, Baines A, Samnotra V, Konstantinopoulos PA. Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032). Gynecol Oncol. 2023 11; 178:161-169. PMID: 37890345; PMCID: PMC11185194.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    22. Eskander RN, Moore KN, Monk BJ, Herzog TJ, Annunziata CM, O'Malley DM, Coleman RL. Overcoming the challenges of drug development in platinum-resistant ovarian cancer. Front Oncol. 2023; 13:1258228. PMID: 37916177; PMCID: PMC10616588.
      Citations: 2     
    23. Oza AM, Grisham RN, Vergote I, Banerjee S, Drill E, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Cibula D, Moore KN, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Kristensen G, Clamp A, Farley J, Iyer G, Ray-Coquard I, Monk BJ. Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer. Clin Cancer Res. 2023 Oct 13; 29(20):4068-4075. PMID: 37581616; PMCID: PMC10570675.
      Citations: 2     Fields:    
    24. Bogani G, Ray-Coquard I, Mutch D, Vergote I, Ramirez PT, Prat J, Concin N, Ngoi NYL, Coleman RL, Enomoto T, Takehara K, Denys H, Lorusso D, Takano M, Sagae S, Wimberger P, Segev Y, Kim SI, Kim JW, Herrera F, Mariani A, Brooks RA, Tan D, Paolini B, Chiappa V, Longo M, Raspagliesi F, Benedetti Panici P, Di Donato V, Caruso G, Colombo N, Pignata S, Zannoni G, Scambia G, Monk BJ. Gestational choriocarcinoma. Int J Gynecol Cancer. 2023 10 02; 33(10):1504-1514. PMID: 37758451.
      Citations: 1     Fields:    Translation:Humans
    25. Algera MD, Morton R, Sundar SS, Farrell R, van Driel WJ, Brennan D, Rijken MJ, Sfeir S, Allen L, Eiken M, Coleman RL, collaborators of the Global Equality in Ovarian Cancer Care project group. Exploring international differences in ovarian cancer care: a survey report on global patterns of care, current practices, and barriers. Int J Gynecol Cancer. 2023 10 02; 33(10):1612-1620. PMID: 37591611; PMCID: PMC10579489.
      Citations:    Fields:    Translation:Humans
    26. Goulden S, Shen Q, Coleman RL, Mathews C, Hunger M, Pahwa A, Schade R. Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm. J Health Econ Outcomes Res. 2023; 10(2):53-61. PMID: 37701519; PMCID: PMC10493167.
      Citations:    
    27. Caruso G, Coleman RL, Aletti G, Multinu F, Botticelli A, Palaia I, Cliby W, Colombo N. Systemic therapy de-escalation in advanced ovarian cancer: a new era on the horizon? Int J Gynecol Cancer. 2023 09 04; 33(9):1448-1457. PMID: 37597852.
      Citations:    Fields:    Translation:Humans
    28. Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW. A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer. Int J Gynecol Cancer. 2023 09 04; 33(9):1458-1463. PMID: 37666539.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    29. Grisham RN, Slomovitz BM, Andrews N, Banerjee S, Brown J, Carey MS, Chui H, Coleman RL, Fader AN, Gaillard S, Gourley C, Sood AK, Monk BJ, Moore KN, Ray-Coquard I, Shih IM, Westin SN, Wong KK, Gershenson DM. Low-grade serous ovarian cancer: expert consensus report on the state of the science. Int J Gynecol Cancer. 2023 09 04; 33(9):1331-1344. PMID: 37591609; PMCID: PMC10511962.
      Citations:    Fields:    Translation:Humans
    30. Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, Colombo N, Van Gorp T, Konner JA, Marin MR, Harter P, Murphy CG, Method M, Coleman RL, Wang J, Noble E, Esteves B. Reply to Z.R. McCaw et al. J Clin Oncol. 2023 Oct 10; 41(29):4705-4706. PMID: 37535884.
      Citations: 1     Fields:    
    31. Levin G, Harrison R, Ledermann J, Meyer R, Coleman RL, Ramirez PT. Evaluating open access publication and research impact in gynecologic oncology. Int J Gynecol Cancer. 2023 07 03; 33(7):1112-1117. PMID: 37220951.
      Citations:    Fields:    Translation:Humans
    32. Coleman RL. Highlights from the 2023 American Society of Clinical Oncology Annual Meeting: gynecologic cancer. Clin Adv Hematol Oncol. 2023 07; 21(7):362-364. PMID: 37477995.
      Citations:    Fields:    Translation:Humans
    33. Herzog TJ, Hays JL, Barlin JN, Buscema J, Cloven NG, Kong LR, Tyagi NK, Lanneau GS, Long BJ, Marsh RL, Seward SM, Starks DC, Welch S, Moore KN, Konstantinopoulos PA, Gilbert L, Monk BJ, O'Malley DM, Chen X, Dalal R, Coleman RL, Sehouli J. ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer. Future Oncol. 2023 Jul; 19(23):1577-1591. PMID: 37334673.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    34. Monk BJ, Coleman RL, Mirza MR. Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: opposing views of the US Food and Drug Administration and European Medicines Agency. Int J Gynecol Cancer. 2023 06 05; 33(6):1008-1009. PMID: 37024238.
      Citations:    Fields:    Translation:Humans
    35. Peipert JD, Goble S, Isaacson J, Tang X, Wallace K, Coleman RL, Ledermann JA, Cella D. Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial. Gynecol Oncol. 2023 08; 175:1-7. PMID: 37262961.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    36. Bogani G, Monk BJ, Coleman RL, Vergote I, Oakin A, Ray-Coquard I, Mariani A, Scambia G, Raspagliesi F, Bolognese B. Selinexor in patients with advanced and recurrent endometrial cancer. Curr Probl Cancer. 2023 12; 47(6):100963. PMID: 37271639.
      Citations: 2     Fields:    Translation:HumansCells
    37. Coleman RL. PARP inhibitor era: current status and future directions. Int J Gynecol Cancer. 2023 04 03; 33(4):444-445. PMID: 36958753.
      Citations:    Fields:    Translation:Humans
    38. El-Swaify ST, Laban M, Ali SH, Sabbour M, Refaat MA, Farrag N, Ibrahim EA, Coleman RL. Can fluorescence-guided surgery improve optimal surgical treatment for ovarian cancer? A systematic scoping review of clinical studies. Int J Gynecol Cancer. 2023 04 03; 33(4):549-561. PMID: 36707085.
      Citations: 1     Fields:    Translation:Humans
    39. Santin AD, Vergote I, Gonz?lez-Mart?n A, Moore K, Oaknin A, Romero I, Diab S, Copeland LJ, Monk BJ, Coleman RL, Herzog TJ, Siegel J, Kasten L, Schlicker A, Schulz A, K?chert K, Walter AO, Childs BH, Elbi C, Bulat I. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study. Int J Gynecol Cancer. 2023 04 03; 33(4):562-570. PMID: 36564099; PMCID: PMC10086500.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    40. Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Nov?k Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA, RUBY Investigators. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023 06 08; 388(23):2145-2158. PMID: 36972026.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    41. Tolcher A, Hamilton E, Coleman RL. The evolving landscape of antibody-drug conjugates in gynecologic cancers. Cancer Treat Rev. 2023 May; 116:102546. PMID: 37023499.
      Citations: 1     Fields:    Translation:Humans
    42. Karpel HC, Slomovitz B, Coleman RL, Pothuri B. Treatment options for molecular subtypes of endometrial cancer in 2023. Curr Opin Obstet Gynecol. 2023 06 01; 35(3):270-278. PMID: 36943683.
      Citations:    Fields:    Translation:Humans
    43. Chelariu-Raicu A, Mahner S, Moore KN, Lorusso D, Coleman RL. Integrating antibody drug conjugates in the management of gynecologic cancers. Int J Gynecol Cancer. 2023 03 06; 33(3):420-429. PMID: 36878560.
      Citations: 1     Fields:    Translation:Humans
    44. Madariaga A, Coleman RL, Gonz?lez Mart?n A. Novel therapies leading to a new landscape in gynecologic tumors. Int J Gynecol Cancer. 2023 03 06; 33(3):321-322. PMID: 36878568.
      Citations: 1     Fields:    Translation:Humans
    45. Karpel H, Slomovitz B, Coleman RL, Pothuri B. Biomarker-driven therapy in endometrial cancer. Int J Gynecol Cancer. 2023 03 06; 33(3):343-350. PMID: 36878569.
      Citations: 1     Fields:    Translation:Humans
    46. Jiao XD, Qin BD, Wang Z, Liu K, Wu Y, Ling Y, Qin WX, Wang MM, Yuan LY, Barreto SG, Kim AW, Mak K, Li H, Xu YY, Qiu XM, Wu M, Jin M, Xu LC, Zhong Y, Yang H, Chen XQ, Zeng Y, Shi J, Zhu WY, Ding QQ, Jia W, Liu SF, Zhou JJ, Shen H, Yao SH, Guo ZJ, Li T, Zhou PJ, Dong XW, Lu WF, Coleman RL, Akce M, Akladios C, Puccetti F, Zang YS. Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway). Front Oncol. 2023; 13:860711. PMID: 36910668; PMCID: PMC9995917.
      Citations:    
    47. Bogani G, Coleman RL, Vergote I, Raspagliesi F, Lorusso D, Monk BJ. Tisotumab vedotin in recurrent or metastatic cervical cancer. Curr Probl Cancer. 2023 06; 47(3):100952. PMID: 36842202.
      Citations: 1     Fields:    Translation:Humans
    48. O'Malley DM, Ledermann JA, Coleman RL. Response to letter to the editor "AML and MDS associated with PARP inhibitor treatment of ovarian cancer". Gynecol Oncol. 2023 04; 171:164-165. PMID: 36774327.
      Citations:    Fields:    Translation:Humans
    49. Herzog TJ, Pignata S, Ghamande SA, Rubio MJ, Fujiwara K, Vulsteke C, Armstrong DK, Sehouli J, Coleman RL, Gabra H, Scambia G, Monk BJ, Arranz JA, Ushijima K, Hanna R, Zamagni C, Wenham RM, Gonz?lez-Mart?n A, Slomovitz B, Jia Y, Ramsay L, Tewari KS, Weil SC, Vergote IB. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. Gynecol Oncol. 2023 03; 170:300-308. PMID: 36758420.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    50. Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Caruso G, Enomoto T, Takehara K, Denys H, Lorusso D, Coleman R, Vaughan MM, Takano M, Provencher DM, Sagae S, Wimberger P, P?ka R, Segev Y, Kim SI, Kim JW, Candido Dos Reis FJ, Ramirez PT, Mariani A, Leitao M, Makker V, Abu-Rustum NR, Vergote I, Zannoni G, Tan D, McCormack M, Paolini B, Bini M, Raspagliesi F, Benedetti Panici P, Di Donato V, Muzii L, Colombo N, Pignata S, Scambia G, Monk BJ. Endometrial carcinosarcoma. Int J Gynecol Cancer. 2023 02 06; 33(2):147-174. PMID: 36585027.
      Citations:    Fields:    Translation:Humans
    51. Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, Colombo N, Van Gorp T, Konner JA, Marin MR, Harter P, Murphy CG, Wang J, Noble E, Esteves B, Method M, Coleman RL. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. J Clin Oncol. 2023 05 01; 41(13):2436-2445. PMID: 36716407; PMCID: PMC10150846.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    52. Prescott LS, Vergote I, Sun CC, Bodurka DC, Coleman RL. Transfusion use and effect on progression-free, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer: evaluation of the European Organization for Research and Treatment EORTC-55971 Cohort. Int J Gynecol Cancer. 2023 01 03; 33(1):1-9. PMID: 36356982; PMCID: PMC10046328.
      Citations:    Fields:    Translation:Humans
    53. Richardson MT, Attwood K, Smith G, Liang SY, LaVigne Mager K, Tewari KS, Coleman RL, Kapp DS, Chan JK, Monk BJ. Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey. Cancer Control. 2023 Jan-Dec; 30:10732748231182795. PMID: 37646470; PMCID: PMC10469236.
      Citations:    Fields:    Translation:Humans
    54. Mizuno M, Ito K, Nakai H, Kato H, Kamiura S, Ushijima K, Nagao S, Takano H, Okadome M, Takekuma M, Tokunaga H, Nagase S, Aoki D, Coleman RL, Nishimura Y, Ratajczak CK, Hashiba H, Xiong H, Katsumata N, Enomoto T, Okamoto A. Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial. Int J Clin Oncol. 2023 Jan; 28(1):163-174. PMID: 36534262; PMCID: PMC9823063.
      Citations: 1     Fields:    
    55. Robertson JFR, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Horgan K, Rauchhaus P, Littleford R, Amy Cheung SY, Cullberg M, de Bruin EC, Koulai L, Lindemann JPO, Pass M, Rugman P, Schiavon G, Deb R, Finlay P, Foxley A, Gee JMW. Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT). Clin Cancer Res. 2022 Dec 15; 28(24):5469. PMID: 36519303.
      Citations: 1     Fields:    
    56. Mathews C, Lorusso D, Coleman RL, Boklage S, Garside J. An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer. Oncologist. 2022 12 09; 27(12):1058-1066. PMID: 36124638; PMCID: PMC9732237.
      Citations:    
    57. Francis PA, Fleming GF, L?ng I, Ciruelos EM, Bonnefoi HR, Bellet M, Bernardo A, Climent MA, Martino S, Bermejo B, Burstein HJ, Davidson NE, Geyer CE, Walley BA, Ingle JN, Coleman RE, M?ller B, Le Du F, Loibl S, Winer EP, Ruepp B, Loi S, Colleoni M, Coates AS, Gelber RD, Goldhirsch A, Regan MM, SOFT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partner. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. J Clin Oncol. 2023 03 01; 41(7):1370-1375. PMID: 36493334; PMCID: PMC10419521.
      Citations:    Fields:    Translation:Humans
    58. Sherertz T, Jhingran A, Biagioli M, Gaffney D, Elshaikh M, Coleman RL, Harkenrider M, Kidd EA, Jolly S, Yashar C, Portelance L, Wahl A, Venkatesan A, Li L, Small W, American Radium Society. Executive summary of the American Radium Society appropriate use criteria for management of uterine clear cell and serous carcinomas. Int J Gynecol Cancer. 2022 12 05; 32(12):1549-1554. PMID: 36423958.
      Citations: 1     Fields:    
    59. Rocconi RP, Monk BJ, Walter A, Herzog TJ, Galanis E, Manning L, Bognar E, Wallraven G, Stanbery L, Aaron P, Senzer N, Coleman RL, Nemunaitis J. Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680]. Gynecol Oncol. 2023 Feb; 169:173. PMID: 36456375.
      Citations:    Fields:    
    60. Westin SN, Fu S, Tsimberidou A, Piha-Paul S, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Leung CH, Lin H, Hong DS, Pant S, Carter B, Jazaeri A, Gershenson D, Sood AK, Coleman RL, Shah J, Meric-Bernstam F, Naing A. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol. 2023 01; 168:76-82. PMID: 36423446; PMCID: PMC9797438.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    61. O'Malley DM, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, Swisher EM, Maloney L, Goble S, Lin KK, Kwan T, Ledermann JA, Coleman RL. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma. Gynecol Oncol. 2022 Dec; 167(3):404-413. PMID: 36273926; PMCID: PMC10339359.
      Citations: 4     Fields:    Translation:Humans
    62. You B, Purdy C, Copeland LJ, Swisher EM, Bookman MA, Fleming G, Coleman R, Randall LM, Tewari KS, Monk BJ, Mannel RS, Walker JL, Cappuccini F, Cohn D, Muzaffar M, Mutch D, Wahner-Hendrickson A, Martin L, Colomban O, Burger RA. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. J Clin Oncol. 2022 12 01; 40(34):3965-3974. PMID: 36252167; PMCID: PMC9746742.
      Citations: 6     Fields:    Translation:Humans
    63. Monk BJ, Fujiwara K, O'Malley DM, Coleman RL, McNeish IA, Lin KK, Hume S, Kristeleit RS. Reply to C. Marchetti et al. J Clin Oncol. 2023 02 01; 41(4):936-938. PMID: 36201707.
      Citations:    Fields:    
    64. Rocconi RP, Stanbery L, Tang M, Walter A, Monk BJ, Herzog TJ, Coleman RL, Manning L, Wallraven G, Horvath S, Bognar E, Senzer N, Brun S, Nemunaitis J, Madeira da Silva L. ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer. Commun Med (Lond). 2022; 2:106. PMID: 36051466; PMCID: PMC9424215.
      Citations:    
    65. Alholm Z, He D, Ting J, Zhang YJ, Sudharshan L, Leong T, Coleman RL, Monk BJ. Real-world treatment drop-off among recurrent or metastatic cervical cancer patients: A US community oncology-based analysis. Gynecol Oncol. 2022 09; 166(3):567-575. PMID: 35914979.
      Citations:    
    66. Coleman R. Bone-Targeted Agents and Metastasis Prevention. Cancers (Basel). 2022 Jul 26; 14(15). PMID: 35892899; PMCID: PMC9367604.
      Citations:    
    67. Sehgal V, Hosmane B, Huang X, Ansell PJ, Dinh MH, Bell-McGuinn K, Luo X, Fleming GF, Friedlander M, Bookman MA, Moore KN, Steffensen KD, Coleman RL, Swisher EM, You B. CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. J Clin Oncol. 2023 01 01; 41(1):107-116. PMID: 35867965; PMCID: PMC9788978.
      Citations:    Fields:    
    68. Chase DM, Backes F, Han S, Graybill W, Mirza MR, Pothuri B, Mangili G, O'Malley DM, Willmott L, Coleman RL, Safra T, Heinzelmann-Schwarz V, Lorusso D, Karl FM, Woodward T, Monk BJ, PRIMA/ENGOT-OV26/GOG-3012 Investigators, Mar?n MR, Berton D, Baumann K, Gonzalez-Martin A. Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial. Gynecol Oncol. 2022 09; 166(3):494-502. PMID: 35851489.
      Citations:    Fields:    
    69. Winter M, Coleman R, Kendall J, Palmieri C, Twelves C, Howell S, MacPherson I, Wilson C, Purohit K, Gath J, Taylor C, Eastell R, Murden G, Brown SR, Rathbone E, Brown J. A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo?) in breast cancer patients with BONe metastases: CARBON trial results. J Bone Oncol. 2022 Aug; 35:100442. PMID: 35800293; PMCID: PMC9253642.
      Citations:    
    70. Monk BJ, Parkinson C, Lim MC, O'Malley DM, Oaknin A, Wilson MK, Coleman RL, Lorusso D, Bessette P, Ghamande S, Christopoulou A, Prendergast E, Demirkiran F, Mikheeva O, Yeku O, Chudecka-Glaz A, Schenker M, Littell RD, Safra T, Chou HH, Morgan MA, Barlin JN, Van Gorp T, Ueland F, Lindahl G, Anderson C, Collins DC, Moore K, Marme F, Westin SN, McNeish IA, Shih D, Lin KK, Goble S, Hume S, Fujiwara K, Kristeleit RS, Provencher D, Droch?tek V. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022 12 01; 40(34):3952-3964. PMID: 35658487; PMCID: PMC9746782.
      Citations:    Fields:    
    71. Chambers LM, O'Malley DM, Coleman RL, Herzog TJ. Is there a "low-risk" patient population in advanced epithelial ovarian cancer?: a critical analysis. Am J Obstet Gynecol. 2022 Nov; 227(5):728-734. PMID: 35640700.
      Citations:    Fields:    
    72. Handley KF, Sood AK, Molin GZD, Westin SN, Meyer LA, Fellman B, Soliman PT, Coleman RL, Fleming ND. Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes. Gynecol Oncol. 2022 07; 166(1):50-56. PMID: 35599168.
      Citations:    Fields:    Translation:Humans
    73. Pothuri B, Eskander RN, Randall LM, O'Malley DM, Slomovitz B, Moore KN, Herzog TJ, Coleman RL, Copeland LJ, Monk BJ. Practice changing cervical cancer clinical trials. Gynecol Oncol. 2022 06; 165(3):410-412. PMID: 35461731.
      Citations:    Fields:    Translation:Humans
    74. Stover EH, Xiong N, Myers AP, Tayob N, Engvold V, Polak M, Broaddus RR, Makker V, Drapkin R, Liu JF, Horowitz NS, Meric-Bernstam F, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN, Konstantinopoulos PA. A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecol Oncol Rep. 2022 Apr; 40:100974. PMID: 35434236; PMCID: PMC9011027.
      Citations:    
    75. Robert NJ, Espirito JL, Chen L, Nwokeji E, Karhade M, Evangelist M, Spira A, Neubauer M, Bullock S, Walberg J, Cheng SK, Coleman RL. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network. Lung Cancer. 2022 04; 166:197-204. PMID: 35313244.
      Citations:    Fields:    Translation:Humans
    76. Kim SK, Ursell P, Coleman RL, Monk BJ, Vergote I. Mitigation and management strategies for ocular events associated with tisotumab vedotin. Gynecol Oncol. 2022 05; 165(2):385-392. PMID: 35277279.
      Citations:    Fields:    Translation:Humans
    77. Lorusso D, Guy H, Samyshkin Y, Hawkes C, Estenson K, Coleman RL. Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer. Cancers (Basel). 2022 Mar 02; 14(5). PMID: 35267593; PMCID: PMC8909094.
      Citations:    
    78. Chou B, Prasad Venkatesulu B, Coleman RL, Harkenrider M, Small W. Management of stage I and II cervical cancer: a review. Int J Gynecol Cancer. 2022 03; 32(3):216-224. PMID: 35256406.
      Citations:    Fields:    Translation:Humans
    79. Coleman R, Chan A, Cameron D, Costa L, Dowsett M, Harrison D, Howell A, Lacombe D, MacKenzie M, McIntosh S, Morgan A, Piccart M, Spanic T, Barrios C, Martin M. Code of practice needed for samples donated by trial participants. Lancet Oncol. 2022 03; 23(3):e89-e90. PMID: 35240091.
      Citations:    Fields:    Translation:Humans
    80. LaFargue CJ, Handley KF, Fleming ND, Nick AM, Chelariu-Raicu A, Fellman B, Castellano T, Ogasawara A, Hom-Tedla M, Blake EA, da Costa AABA, Crim AK, Rauh-Hain A, Westin SN, Coleman RL, Matsuo K, Baiocchi G, Hasegawa K, Moore K, Sood AK. Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. Gynecol Oncol. 2022 04; 165(1):82-89. PMID: 35216808; PMCID: PMC8969169.
      Citations:    Fields:    Translation:Humans
    81. Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, Millan D, Coleman RL, Moore KN, Banerjee S, Connolly K, Secord AA, O'Malley DM, Dorigo O, Gaillard S, Gabra H, Slomovitz B, Hanjani P, Farley J, Churchman M, Ewing A, Hollis RL, Herrington CS, Huang HQ, Wenzel L, Gourley C. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022 02 05; 399(10324):541-553. PMID: 35123694; PMCID: PMC8819271.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    82. Slomovitz BM, Filiaci VL, Walker JL, Taub MC, Finkelstein KA, Moroney JW, Fleury AC, Muller CY, Holman LL, Copeland LJ, Miller DS, Coleman RL. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. Gynecol Oncol. 2022 03; 164(3):481-491. PMID: 35063278.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    83. Bogani G, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Lorusso D, Coleman R, Vaughan MM, Takano M, Sagae S, Wimberger P, Segev Y, Kim SI, Kim JW, Candido Dos Reis FJ, Mariani A, Leitao MM, Makker V, Rustum NA, Vergote I, Zannoni GF, Tan DSP, McCormack M, Bini M, Lopez S, Raspagliesi F, Panici PB, di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ, Ray-Coquard I, Provencher D, P?ka R. Clear cell carcinoma of the endometrium. Gynecol Oncol. 2022 03; 164(3):658-666. PMID: 35063279.
      Citations:    Fields:    Translation:Humans
    84. Aghajanian C, Swisher EM, Okamoto A, Steffensen KD, Bookman MA, Fleming GF, Friedlander M, Moore KN, Tewari KS, O'Malley DM, Chan JK, Ratajczak C, Hashiba H, Wu M, Dinh MH, Coleman RL. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial. Gynecol Oncol. 2022 02; 164(2):278-287. PMID: 34930617; PMCID: PMC9399938.
      Citations:    Fields:    Translation:Humans
    85. Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL, Steffensen KD. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253. PMID: 34906376.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    86. Goyal A, Mann GB, Fallowfield L, Duley L, Reed M, Dodwell D, Coleman RE, Fakis A, Newcombe R, Jenkins V, Whitham D, Childs M, Whynes D, Keeley V, Ellis I, Fairbrother P, Sadiq S, Monson K, Montgomery A, Tan W, Vale L, Homer T, Badger H, Haines RH, Lewis M, Megias D, Nabi Z, Singh P, Caraman A, Miles E, POSNOC Trialists. POSNOC-POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes. BMJ Open. 2021 12 02; 11(12):e054365. PMID: 34857578; PMCID: PMC8640630.
      Citations: 3     Fields:    Translation:Humans
    87. Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Aghajanian C, Lorusso D, Colombo N, Dean A, Weberpals J, Severson E, Vo LT, Goble S, Maloney L, Harding T, Kaufmann SH, Ledermann JA, Coleman RL, McNeish IA, Lin KK, Swisher EM. Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. JAMA Oncol. 2021 Dec 01; 7(12):1772-1781. PMID: 34647981; PMCID: PMC8517887.
      Citations: 5     Fields:    Translation:Humans
    88. DiSilvestro P, Colombo N, Harter P, Ray-Coquard I, Coleman RL, Gonz?lez-Mart?n A. Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift? Cancers (Basel). 2021 Nov 17; 13(22). PMID: 34830911; PMCID: PMC8616471.
      Citations: 3     
    89. Sims TT, Coleman RL, Lain? A, Le Saux O, Ray-Coquard I. Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy. Curr Oncol Rep. 2021 11 09; 23(12):148. PMID: 34751835.
      Citations:    Fields:    Translation:Humans
    90. Yap TA, Coleman RL. The Principles and Practice of PARP Inhibitor Therapy. Cancer J. 2021 Nov-Dec 01; 27(6):430-431. PMID: 34904805; PMCID: PMC8682798.
      Citations:    Fields:    Translation:HumansCells
    91. Smith G, Alholm Z, Coleman RL, Monk BJ. DNA Damage Repair Inhibitors-Combination Therapies. Cancer J. 2021 Nov-Dec 01; 27(6):501-505. PMID: 34904813.
      Citations:    Fields:    Translation:HumansCells
    92. Walter A, Rocconi RP, Monk BJ, Herzog TJ, Manning L, Bognar E, Wallraven G, Aaron P, Horvath S, Tang M, Stanbery L, Coleman RL, Nemunaitis J. Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecol Oncol. 2021 12; 163(3):459-464. PMID: 34702567.
      Citations: 1     Fields:    Translation:Humans
    93. Monk BJ, Coleman RL, Fujiwara K, Wilson MK, Oza AM, Oaknin A, O'Malley DM, Westin SN, Safra T, Herzog TJ, N Eskander R, Lin KK, Shih D, Goble S, Grechko N, Hume S, Maloney L, McNeish IA, Kristeleit RS, Lorusso D, Marm? F. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2021 12; 31(12):1589-1594. PMID: 34593565; PMCID: PMC8666815.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    94. Swisher EM, Kristeleit RS, Oza AM, Tinker AV, Oaknin A, Coleman RL, Burris HA, Aghajanian C, O'Malley DM, Leary A, Welch S, Shapiro GI, Chen LM, Shapira-Frommer R, Kaufmann SH, Goble S, Maloney L, Kwan T, Lin KK, McNeish IA, Ray-Coquard I, Provencher D. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. Gynecol Oncol. 2021 12; 163(3):490-497. PMID: 34602290.
      Citations: 2     Fields:    Translation:Humans
    95. Handley KF, Rodriguez-Aguayo C, Ma S, Stur E, Joseph R, Bayraktar E, Dasari SK, Nguyen N, Powell RT, Sobieski M, Ivan C, Kim M, Umamaheswaran S, Glassman D, Wen Y, Amero P, Stephan C, Coleman RL, Landesman Y, Westin SN, Ram PT, Sood AK. Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Mol Cancer Ther. 2021 12; 20(12):2352-2361. PMID: 34583979; PMCID: PMC8643313.
      Citations:    Fields:    Translation:HumansAnimalsCells
    96. Oaknin A, Oza AM, Lorusso D, Aghajanian C, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, Swisher EM, Cameron T, Maloney L, Goble S, Ledermann JA, Coleman RL, Amenedo Gancedo M, Garc?a-Donas J. Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. Cancer Med. 2021 10; 10(20):7162-7173. PMID: 34549539; PMCID: PMC8525125.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    97. Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365. PMID: 34518313; PMCID: PMC8639651.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    98. Schmeler KM, Humberto Fregnani J, Lopes A, Perrotta M, Tsunoda AT, Ramondetta LM, Manchana T, Crotzer DR, McNally OM, Scambia G, Carvajal JM, Ramalingam P, Fellman BM, Coleman RL, Frumovitz M, Ramirez PT, Pareja R, Lopez Blanco A, Cant?-de-Le?n DF, Riege M, Di Guilmi J, Rendon GJ. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer. Int J Gynecol Cancer. 2021 10; 31(10):1317-1325. PMID: 34493587.
      Citations: 8     Fields:    Translation:Humans
    99. Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S, Murray E, Grieve R, Coleman R, Borley A, Schmidt M, Rautenberg B, Rhein U, Mehta K, Mousa K, Dibble T, Lu XL, von Minckwitz G, Bliss JM, Randomized European Celecoxib Trial (REACT) Trial Management Group and Investigators, Denkert C, Kunze CA. Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. JAMA Oncol. 2021 Sep 01; 7(9):1291-1301. PMID: 34264305; PMCID: PMC8283666.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    100. Fuh KC, Bookman MA, Liu JF, Coleman RL, Herzog TJ, Thaker PH, Monk BJ, Anderson R, McIntyre G, Rangwala R, Moore KN. Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. Gynecol Oncol. 2021 11; 163(2):254-261. PMID: 34474927.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    101. O'Malley DM, Randall LM, Jackson CG, Coleman RL, Hays JL, Moore KN, Naumann RW, Rocconi RP, Slomovitz BM, Tewari KS, Ancukiewicz M, Feliu WO, Monk BJ. RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer. Future Oncol. 2021 Sep; 17(26):3433-3443. PMID: 34409858.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    102. Ma S, Mangala LS, Hu W, Bayaktar E, Yokoi A, Hu W, Pradeep S, Lee S, Piehowski PD, Villar-Prados A, Wu SY, McGuire MH, Lara OD, Rodriguez-Aguayo C, LaFargue CJ, Jennings NB, Rodland KD, Liu T, Kundra V, Ram PT, Ramakrishnan S, Lopez-Berestein G, Coleman RL, Sood AK. CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Rep. 2021 08 17; 36(7):109549. PMID: 34407412; PMCID: PMC8422976.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    103. Wu Y, Huang J, Ivan C, Sun Y, Ma S, Mangala LS, Fellman BM, Urbauer DL, Jennings NB, Ram P, Coleman RL, Hu W, Sood AK. MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. Gynecol Oncol. 2021 10; 163(1):181-190. PMID: 34391578; PMCID: PMC8511168.
      Citations:    Fields:    Translation:HumansAnimalsCells
    104. Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, Matsuo K, Lee JS, Ram P, Coleman RL, Sood AK. Editor's Note: Biologic Effects of Platelet-Derived Growth Factor Receptor a Blockade in Uterine Cancer. Clin Cancer Res. 2021 08 01; 27(15):4449. PMID: 34341054.
      Citations:    Fields:    
    105. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MMK, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Editor's Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2021 08 01; 27(15):4454. PMID: 34341059.
      Citations:    Fields:    
    106. Friedl TWP, Fehm T, Lorenz R, Forstbauer H, Fink V, Bekes I, Huober J, Schneeweiss A, Tesch H, Mahner S, Fasching PA, Beckmann MW, Coleman RE, Janni W, Rack B, M?ller V, Lichtenegger W, Blohmer J, J?ckstock J, Brucker SY, Heinrich G, H?berle L. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Aug 01; 7(8):1149-1157. PMID: 34165508; PMCID: PMC8227465.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    107. Lovero D, D'Oronzo S, Palmirotta R, Cafforio P, Brown J, Wood S, Porta C, Lauricella E, Coleman R, Silvestris F. Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases. Br J Cancer. 2022 02; 126(3):419-429. PMID: 34272498; PMCID: PMC8810805.
      Citations: 2     Fields:    Translation:HumansCells
    108. Coleman R, Zhou Y, Jandial D, Cadieux B, Chan A. Bone Health Outcomes from the International, Multicenter, Randomized, Phase?3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer. Adv Ther. 2021 08; 38(8):4569-4580. PMID: 34185259; PMCID: PMC8342342.
      Citations: 1     Fields:    Translation:Humans
    109. Clamp AR, Lorusso D, Oza AM, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Scambia G, Leary A, Holloway RW, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, Swisher EM, Cameron T, Goble S, Coleman RL, Ledermann JA, Amenedo Gancedo M, Garc?a-Donas J. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. Int J Gynecol Cancer. 2021 07; 31(7):949-958. PMID: 34103386; PMCID: PMC9445915.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    110. Aghajanian C, Bookman MA, Fleming GF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Jackson CG, Sullivan D, Ratajczak CK, Coleman RL. Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. Gynecol Oncol. 2021 08; 162(2):375-381. PMID: 34112513.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    111. Jones RL, Herzog TJ, Patel SR, von Mehren M, Schuetze SM, Van Tine BA, Coleman RL, Knoblauch R, Triantos S, Hu P, Shalaby W, McGowan T, Monk BJ, Demetri GD. Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer Med. 2021 06; 10(11):3565-3574. PMID: 33960681; PMCID: PMC8178483.
      Citations: 1     Fields:    Translation:Humans
    112. Swisher EM, Kwan TT, Oza AM, Tinker AV, Oaknin A, Coleman RL, Aghajanian C, Konecny GE, O'Malley DM, Leary A, Welch S, Chen LM, Wahner Hendrickson AE, Ma L, Ghatage P, Kristeleit RS, Dorigo O, Musafer A, Kaufmann SH, Elvin JA, Lin DI, Chambers SK, Dominy E, Vo LT, Goble S, Maloney L, Giordano H, Harding T, Dobrovic A, Scott CL, Lin KK, McNeish IA, Ray-Coquard I, Provencher D. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat Commun. 2021 05 03; 12(1):2487. PMID: 33941784; PMCID: PMC8093258.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    113. Coleman RL, Lorusso D, Randall L, Cibula D, Lund B, Pignata S, Forget F, Chen M, Harris JR, Smith M, Nicacio LV, Teng MSL, Laenen A, Rangwala R, Manso L, Mirza M, Monk BJ, Vergote I, innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators, Gennigens C, Gonz?lez-Mart?n A, Woelber L, Redondo A, Vindel?v SD. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 05; 22(5):609-619. PMID: 33845034.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    114. Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AK. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021 07; 162(1):65-71. PMID: 33838925; PMCID: PMC8287765.
      Citations: 1     Fields:    Translation:Humans
    115. Coleman RL, Beck JT, Baranda JC, Jacobs I, Smoyer KE, Lee LJ, Askerova Z, McGinnis J, Ganti AK. The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials. Oncology. 2021; 99(7):444-453. PMID: 33823518.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    116. Rocconi RP, Stevens EE, Bottsford-Miller JN, Ghamande SA, Elder J, DeMars LL, Munkarah A, Aaron P, Stanbery L, Wallraven G, Bognar E, Manley M, Horvath S, Manning L, Walter A, Galanis E, Herzog T, Monk BJ, Coleman RL, Nemunaitis J. Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer. Cancer Gene Ther. 2022 03; 29(3-4):369-382. PMID: 33753870.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    117. Konecny GE, Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, Aghajanian C, Coleman RL, O'Malley DM, Leary A, Chen LM, Ma L, Brenton JD, Castro C, Green M, Simmons AD, Beltman J, Harding T, Lin KK, Goble S, Maloney L, Kristeleit RS, McNeish IA, Swisher EM, Xiao JJ, Ray-Coquard I, Provencher D. Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. Gynecol Oncol. 2021 06; 161(3):668-675. PMID: 33752918; PMCID: PMC9535637.
      Citations: 1     Fields:    Translation:Humans
    118. Lee CK, Friedlander ML, Tjokrowidjaja A, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, Bloomfield R, Goble S, Wang P, Glasspool RM, Scott CL, Gynecologic Cancer Intergroup Meta-Analysis Committee, Pujade-Lauraine E. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. Cancer. 2021 07 15; 127(14):2432-2441. PMID: 33740262.
      Citations: 4     Fields:    Translation:Humans
    119. Alholm Z, Monk BJ, Ting J, Pulgar S, Boyd M, Sudharshan L, Bains S, Nicacio L, Coleman RL. Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis. Gynecol Oncol. 2021 05; 161(2):422-428. PMID: 33741208.
      Citations: 1     Fields:    Translation:Humans
    120. Nitecki R, Melamed A, Gockley AA, Floyd J, Krause KJ, Coleman RL, Matulonis UA, Giordano SH, Lu KH, Rauh-Hain JA. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. Gynecol Oncol. 2021 06; 161(3):653-659. PMID: 33736856; PMCID: PMC8164998.
      Citations: 7     Fields:    Translation:Humans
    121. Monk BJ, Coleman RL, Herzog TJ, Moore KN, O'Malley DM, Randall LM, Slomovitz BM, Eskander R, Pothuri B, Reese LL, Mannel RS, Copeland LJ. The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation. Gynecol Oncol. 2021 07; 162(1):203-209. PMID: 33722417.
      Citations:    Fields:    Translation:Humans
    122. Rocconi RP, Monk BJ, Walter A, Herzog TJ, Galanis E, Manning L, Bognar E, Wallraven G, Stanbery L, Aaron P, Senzer N, Coleman RL, Nemunaitis J. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecol Oncol. 2021 06; 161(3):676-680. PMID: 33715892.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    123. Zhong Y, Liu J, Li X, Westin SN, Malpica A, Lawson BC, Lee S, Fellman BM, Coleman RL, Sood AK, Fleming ND. A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers (Basel). 2021 Feb 09; 13(4). PMID: 33572451; PMCID: PMC7916221.
      Citations: 2     
    124. Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Darcy KM, Conrads TP, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, Lopez-Berestein G, Lu KH, Coleman RL, Maxwell GL, Sood AK. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecol Oncol. 2021 03; 160(3):777-785. PMID: 33563487; PMCID: PMC8538374.
      Citations: 4     Fields:    Translation:Humans
    125. Coleman RL, Hu W, Soliman P, Nick A, Ramirez PT, Westin SN, Garcia ME, Zhu Z, Palancia J, Fellman BM, Yuan Y, Ram P, Bischoff F, Schmeler K, Bodurka D, Meyer LA, Sood AK. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol. 2021 04; 161(1):104-112. PMID: 33551196.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    126. Handforth C, Burkinshaw R, Freeman J, Brown JE, Snowden JA, Fearnside J, Coleman RE, Greenfield DM. Correction to: Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer. Support Care Cancer. 2021 Feb; 29(2):1145. PMID: 33216165.
      Citations:    Fields:    
    127. Sestak I, Blake G, Patel R, Cuzick J, Howell A, Coleman R, Eastell R. Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial. Br J Cancer. 2021 04; 124(8):1373-1378. PMID: 33495601; PMCID: PMC8039042.
      Citations: 1     Fields:    Translation:Humans
    128. Eskander RN, Pothuri B, Randall L, O'Malley D, Slomovitz B, Moore K, Coleman R, Herzog T, Monk BJ, Copeland L. Clinical trials, adaptability and the COVID-19 pandemic. Gynecol Oncol Rep. 2021 Feb; 35:100680. PMID: 33319009; PMCID: PMC7723439.
      Citations:    
    129. Coleman RL. The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us? J Gynecol Oncol. 2021 01; 32(1):e20. PMID: 33300315; PMCID: PMC7767661.
      Citations:    Fields:    Translation:Humans
    130. Rocconi RP, Grosen EA, Ghamande SA, Chan JK, Barve MA, Oh J, Tewari D, Morris PC, Stevens EE, Bottsford-Miller JN, Tang M, Aaron P, Stanbery L, Horvath S, Wallraven G, Bognar E, Manning L, Nemunaitis J, Shanahan D, Slomovitz BM, Herzog TJ, Monk BJ, Coleman RL. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Oncol. 2020 12; 21(12):1661-1672. PMID: 33271095.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    131. Chelariu-Raicu A, Nick A, Urban R, Gordinier M, Leuschner C, Bavisotto L, Molin GZD, Whisnant JK, Coleman RL. A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer. Gynecol Oncol. 2021 02; 160(2):418-426. PMID: 33243443.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    132. Fleming ND, Westin SN, Meyer LA, Shafer A, Rauh-Hain JA, Onstad M, Cobb L, Bevers M, Fellman BM, Burzawa J, Bhosale P, Zand B, Jazaeri A, Levenback C, Coleman RL, Soliman PT, Sood AK. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2021 01; 31(1):92-97. PMID: 33154095; PMCID: PMC8266398.
      Citations: 1     Fields:    Translation:Humans
    133. Chelariu-Raicu A, Levenback CF, Slomovitz BM, Wolf J, Bodurka DC, Kavanagh JJ, Morrison C, Gershenson DM, Coleman RL. Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer. Int J Gynecol Cancer. 2020 11; 30(11):1768-1774. PMID: 33037105.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    134. Slomovitz B, de Haydu C, Taub M, Coleman RL, Monk BJ. Asbestos and ovarian cancer: examining the historical evidence. Int J Gynecol Cancer. 2021 01; 31(1):122-128. PMID: 33037108.
      Citations: 4     Fields:    Translation:Humans
    135. Slomovitz BM, Chelariu-Raicu A, Schmeler KM, Lu KH, Gershenson DM, Wolf J, Coleman RL. Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. Int J Gynecol Cancer. 2020 11; 30(11):1733-1737. PMID: 33020204.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    136. Moore KN, Pothuri B, Monk B, Coleman RL. PARP inhibition in recurrent ovarian cancer. Clin Adv Hematol Oncol. 2020 Oct; 18(10):647-655. PMID: 33201871.
      Citations: 1     Fields:    Translation:Humans
    137. Onstad M, Coleman RL, Westin SN. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer. Drugs. 2020 Oct; 80(15):1525-1535. PMID: 32852746; PMCID: PMC7541632.
      Citations: 1     Fields:    Translation:HumansCells
    138. Chan JK, Liang SY, Kapp DS, Chan JE, Herzog TJ, Coleman RL, Monk BJ, Richardson MT. Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance. Gynecol Oncol. 2020 12; 159(3):604-606. PMID: 32994055.
      Citations: 2     Fields:    Translation:Humans
    139. Kim MS, Ma S, Chelariu-Raicu A, Leuschner C, Alila HW, Lee S, Coleman RL, Sood AK. Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer. Mol Cancer Ther. 2020 11; 19(11):2396-2406. PMID: 32943548; PMCID: PMC9399905.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    140. Chelariu-Raicu A, Coleman RL, Zibetti Dal Molin G. The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers. Int J Gynecol Cancer. 2020 10; 30(10):1608-1618. PMID: 32928926.
      Citations:    Fields:    Translation:Humans
    141. Moore KN, Pothuri B, Monk B, Coleman RL. PARP inhibition as frontline therapy in ovarian cancer. Clin Adv Hematol Oncol. 2020 Sep; 18(9):550-556. PMID: 33006584.
      Citations: 2     Fields:    Translation:Humans
    142. Colombo N, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, Swisher EM, Meunier J, Cameron T, Maloney L, Goble S, Bedel J, Ledermann JA, Coleman RL, Gancedo MA, Garc?a-Donas J. The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. Gynecol Oncol. 2020 10; 159(1):101-111. PMID: 32861537; PMCID: PMC8450972.
      Citations: 3     Fields:    Translation:Humans
    143. Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, Swisher EM, Cella D, Meunier J, Goble S, Cameron T, Maloney L, Bedel J, Ledermann JA, Coleman RL, Gancedo MA, Garc?a-Donas J, M?rk AC. Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. J Clin Oncol. 2020 10 20; 38(30):3494-3505. PMID: 32840418; PMCID: PMC7571791.
      Citations: 8     Fields:    Translation:Humans
    144. Monk BJ, Grisham RN, Banerjee S, Mirza MR, Romero I, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, O'Malley DM, Boyd AP, Kristensen G, Clamp A, Vergote I, Kalbacher E, Vuylsteke P, Colombo N, Sehouli J, Churruca C, Ray-Coquard I. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. J Clin Oncol. 2020 11 10; 38(32):3753-3762. PMID: 32822286; PMCID: PMC7655017.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    145. Chelariu-Raicu A, Coleman RL. Breast cancer (BRCA) gene testing in ovarian cancer. Chin Clin Oncol. 2020 Oct; 9(5):63. PMID: 32819112.
      Citations: 1     Fields:    Translation:Humans
    146. Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, Fleming ND, Burzawa JK, Nick AM, Milbourne AM, Yuan Y, Lu KH, Bodurka DC, Coleman RL, Yates MS. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15. PMID: 32805208; PMCID: PMC7855308.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    147. Tewari KS, Sill MW, Coleman RL, Aghajanian C, Mannel R, DiSilvestro PA, Powell M, Randall LM, Farley J, Rubin SC, Monk BJ. Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2020 10; 159(1):79-87. PMID: 32723679; PMCID: PMC7789907.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    148. Nitecki R, Rauh-Hain JA, Melamed A, Scambia G, Coleman RL, Ramirez PT, Fagotti A, Pareja R. Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE). Int J Gynecol Cancer. 2020 09; 30(9):1450-1454. PMID: 32690591; PMCID: PMC7493891.
      Citations: 4     Fields:    Translation:Humans
    149. Fujiwara K, Quinn MA, Coleman RL, Angioli R. Two viral infections in Japan. Int J Gynecol Cancer. 2020 08; 30(8):1258-1259. PMID: 32675255; PMCID: PMC7418619.
      Citations: 1     Fields:    Translation:HumansCells
    150. Obermair A, Baxter E, Brennan DJ, McAlpine JN, Muellerer JJ, van Gent MDJM, Coleman RL, Westin SN, Yates MS, Krakstad C, Janda M, Amant F. Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstet Gynecol Sci. 2020 Jul; 63(4):417-431. PMID: 32689770; PMCID: PMC7393748.
      Citations: 11     
    151. Miyake TM, Pradeep S, Bayraktar E, Stur E, Handley KF, Wu SY, Rodriguez-Aguayo C, Lee JS, Lopez-Berestein G, Coleman RL, Sood AK. NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors. Mol Cancer Ther. 2020 08; 19(8):1727-1735. PMID: 32499298; PMCID: PMC7415525.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    152. Frumovitz M, Obermair A, Coleman RL, Ribero R, Bernardini MQ, Buda A, Zhu T, Land RP, Nicklin J, Asher R, Robledo KP, Gebski V, Ramirez PT, Pareja R, Lopez A, Isla D, Rendon G, Moretti-Marquez R, Zevallos A, Vieira MA. Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2020 06; 21(6):851-860. PMID: 32502445; PMCID: PMC9762514.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    153. Margul D, Coleman RL, Herzog TJ. The current status of secondary cytoreduction in ovarian cancer: a systematic review. Clin Adv Hematol Oncol. 2020 Jun; 18(6):332-343. PMID: 32649655.
      Citations: 3     Fields:    Translation:Humans
    154. Elshaikh MA, Modh A, Jhingran A, Biagioli MC, Coleman RL, Gaffney DK, Harkenrider MM, Heskett K, Jolly S, Kidd E, Lee LJ, Li L, Portelance L, Sherertz T, Venkatessan AM, Wahl AO, Yashar CM, Small W. Executive summary of the American Radium Society? Appropriate Use Criteria for management of uterine carcinosarcoma. Gynecol Oncol. 2020 08; 158(2):460-466. PMID: 32475772.
      Citations: 1     Fields:    Translation:Humans
    155. Kurnit KC, Avila M, Hinchcliff EM, Coleman RL, Westin SN. PARP inhibition in the ovarian cancer patient: Current approvals and future directions. Pharmacol Ther. 2020 09; 213:107588. PMID: 32450190; PMCID: PMC8331065.
      Citations: 4     Fields:    Translation:Humans
    156. Baxter E, Brennan DJ, McAlpine JN, Mueller JJ, van Gent MDJM, Huntsman DG, Coleman RL, Westin SN, Yates MS, Krakstad C, Quinn MA, Janda M, Obermair A, Amant F. Improving response to progestin treatment of low-grade endometrial cancer. Int J Gynecol Cancer. 2020 11; 30(11):1811-1823. PMID: 32381512; PMCID: PMC8445150.
      Citations: 6     Fields:    Translation:Humans
    157. Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL, Gancedo MA, Garc?a-Donas J. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 05; 21(5):710-722. PMID: 32359490; PMCID: PMC8210534.
      Citations: 15     Fields:    Translation:Humans
    158. Monk BJ, Coleman RL, Moore KN, Herzog TJ, Secord AA, Matulonis UA, Slomovitz BM, Guntupalli SR, O'Malley DM. COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies. Gynecol Oncol. 2020 07; 158(1):34-36. PMID: 32370991; PMCID: PMC7188656.
      Citations: 3     Fields:    Translation:HumansCellsPHPublic Health
    159. Armbruster SD, Fellman BM, Jhingran A, Eifel PJ, Klopp AH, Coleman RL, Ramondetta LM, Frumovitz M. A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. Support Care Cancer. 2021 Jan; 29(1):213-222. PMID: 32338316.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    160. Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502. PMID: 32294438; PMCID: PMC7234854.
      Citations: 26     Fields:    Translation:Humans
    161. Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL. Bevacizumab (Avastin?) in cancer treatment: A review of 15?years of clinical experience and future outlook. Cancer Treat Rev. 2020 Jun; 86:102017. PMID: 32335505.
      Citations: 151     Fields:    Translation:Humans
    162. Monk BJ, Herzog TJ, Wang G, Triantos S, Maul S, Knoblauch R, McGowan T, Shalaby WSW, Coleman RL. Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer. Data Brief. 2020 Jun; 30:105465. PMID: 32346557; PMCID: PMC7178483.
      Citations: 1     
    163. Coleman RL. Innovation abounds in cancer therapy. Int J Gynecol Cancer. 2020 04; 30(4):424-425. PMID: 32193218.
      Citations:    Fields:    Translation:Humans
    164. Coleman R, Zhou Y, Chan A, D-CARE investigators. Adjuvant denosumab in early breast cancer - Authors' reply. Lancet Oncol. 2020 03; 21(3):e125. PMID: 32135109.
      Citations: 1     Fields:    
    165. Arend R, Westin SN, Coleman RL. Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review. Int J Gynecol Cancer. 2020 05; 30(5):684-694. PMID: 32079709.
      Citations: 2     Fields:    Translation:HumansCells
    166. Coleman RL. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. Reply. N Engl J Med. 2020 02 13; 382(7):686. PMID: 32053314.
      Citations: 1     Fields:    Translation:Humans
    167. Rees M, Angioli R, Coleman RL, Glasspool R, Plotti F, Simoncini T, Terranova C. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas. 2020 Apr; 134:56-61. PMID: 32059825.
      Citations: 6     Fields:    Translation:Humans
    168. Rees M, Angioli R, Coleman RL, Glasspool RM, Plotti F, Simoncini T, Terranova C. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Int J Gynecol Cancer. 2020 04; 30(4):428-433. PMID: 32046979.
      Citations: 1     Fields:    Translation:Humans
    169. Coleman RL, Handley KF, Burger R, Stagg R, Sood AK, Moore KN, Molin GZD. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. Gynecol Oncol. 2020 05; 157(2):386-391. PMID: 32037195.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    170. Lee EK, Tan-Wasielewski Z, Aghajanian C, Coleman RL, Curtis J, Hirsch MS, Matulonis UA, Cantley LC, Mills GB, Doyle LA, Liu JF. Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). Gynecol Oncol Rep. 2020 May; 32:100546. PMID: 32083163; PMCID: PMC7021536.
      Citations: 3     
    171. Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O'Malley DM, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Gershenson DM, Lecuru F, Fern?ndez ML, Ray-Coquard I. Low-grade serous ovarian cancer: State of the science. Gynecol Oncol. 2020 03; 156(3):715-725. PMID: 31969252.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    172. Coleman R, Brown J, Rathbone E, Flanagan L, Reid A, Kendall J, Howell S, Twelves C, Palmieri C, Anand A, MacPherson I, Brown S. CApecitabine plus Radium-223 (Xofigo?) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial. Trials. 2020 Jan 15; 21(1):89. PMID: 31941523; PMCID: PMC6961242.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    173. Kittaneh M, Badve S, Caldera H, Coleman R, Goetz MP, Mahtani R, Mamounas E, Kalinsky K, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Traina T, Vogel C. Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). Clin Breast Cancer. 2020 06; 20(3):183-193. PMID: 32014370.
      Citations: 7     Fields:    Translation:Humans
    174. Monk BJ, Herzog TJ, Wang G, Triantos S, Maul S, Knoblauch R, McGowan T, Shalaby WSW, Coleman RL. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer. Gynecol Oncol. 2020 03; 156(3):535-544. PMID: 31924332.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    175. Herzog TJ, Secord AA, Coleman RL, Naumann RW. European society of medical oncology (ESMO) 2019 meeting report features practice changing data in gynecologic malignancies. Gynecol Oncol. 2020 02; 156(2):265-270. PMID: 31911006.
      Citations:    Fields:    Translation:Humans
    176. Lin R, Coleman RL, Yuan Y. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy. J Natl Cancer Inst. 2020 01 01; 112(1):38-45. PMID: 30924863; PMCID: PMC8204709.
      Citations: 5     Fields:    Translation:Humans
    177. Naumann RW, Coleman RL, Brown J, Moore KN. Corrigendum to "Phase III trials in ovarian cancer: The evolving landscape of front line therapy" [Gynecol. Oncol. 153 (2019) 436-444]. Gynecol Oncol. 2020 Feb; 156(2):512-513. PMID: 31859001.
      Citations:    Fields:    
    178. Robertson JFR, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Horgan K, Rauchhaus P, Littleford R, Cheung SYA, Cullberg M, de Bruin EC, Koulai L, Lindemann JPO, Pass M, Rugman P, Schiavon G, Deb R, Finlay P, Foxley A, Gee JMW. Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT). Clin Cancer Res. 2020 04 01; 26(7):1574-1585. PMID: 31836609.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    179. Myers AP, Konstantinopoulos PA, Barry WT, Luo W, Broaddus RR, Makker V, Drapkin R, Liu J, Doyle A, Horowitz NS, Meric-Bernstam F, Birrer M, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN. Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. Int J Cancer. 2020 07 15; 147(2):413-422. PMID: 31714586; PMCID: PMC7214201.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    180. Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, Arkenau HT, Spicer JF, Jones R, Forster MD, Johnson ML, Thistlethwaite FC, Rangwala RA, Ghatta S, Windfeld K, Harris JR, Lassen UN, Coleman RL, Machiels JP, Cornez N, Gennigens C. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clin Cancer Res. 2020 03 15; 26(6):1220-1228. PMID: 31796521.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    181. Coleman R, Finkelstein DM, Iwata H, Glaspy J, Tonkin K, Deleu I, Sohn J, Crown J, Delaloge S, Dai T, Zhou Y, Jandial D, Chan A, Barrios C, Martin M, Hegg R, Peria?ez AM. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020 01; 21(1):60-72. PMID: 31806543.
      Citations: 49     Fields:    Translation:HumansCTClinical Trials
    182. Zibetti Dal Molin G, Westin SN, Msaouel P, Gomes LM, Dickens A, Coleman RL. Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. Int J Gynecol Cancer. 2020 01; 30(1):89-93. PMID: 31792084.
      Citations: 9     Fields:    Translation:Humans
    183. Maoz A, Ciccone MA, Matsuzaki S, Coleman RL, Matsuo K. Emerging serine-threonine kinase inhibitors for treating ovarian cancer. Expert Opin Emerg Drugs. 2019 12; 24(4):239-253. PMID: 31755325; PMCID: PMC7526049.
      Citations: 2     Fields:    Translation:Humans
    184. Lara OD, Krishnan S, Wang Z, Corvigno S, Zhong Y, Lyons Y, Dood R, Hu W, Qi L, Liu J, Coleman RL, Westin SN, Fleming ND, Cristini V, Rao A, Burks J, Sood AK. Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Sci Rep. 2019 11 26; 9(1):17589. PMID: 31772388; PMCID: PMC6879510.
      Citations: 5     Fields:    Translation:HumansCells
    185. Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019 11 14; 381(20):1929-1939. PMID: 31722153; PMCID: PMC6941470.
      Citations: 60     Fields:    Translation:HumansCTClinical Trials
    186. Walsh JS, Marshall H, Smith IL, Greenfield DM, Swain J, Best E, Ashton J, Brown JM, Huddart R, Coleman RE, Snowden JA, Ross RJ. Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial. PLoS Med. 2019 11; 16(11):e1002960. PMID: 31714912; PMCID: PMC6850530.
      Citations: 5     Fields:    Translation:Humans
    187. Coleman R. Clinical benefits of bone targeted agents in early breast cancer. Breast. 2019 Nov; 48 Suppl 1:S92-S96. PMID: 31839171.
      Citations: 3     Fields:    Translation:Humans
    188. Roh JW, Choi JE, Han HD, Hu W, Matsuo K, Nishimura M, Lee JS, Kwon SY, Cho CH, Kim J, Coleman RL, Lopez-Bernstein G, Sood AK. Clinical and biological significance of EZH2 expression in endometrial cancer. Cancer Biol Ther. 2020; 21(2):147-156. PMID: 31640461; PMCID: PMC7012102.
      Citations: 10     Fields:    Translation:HumansCells
    189. Soliman PT, Westin SN, Iglesias DA, Fellman BM, Yuan Y, Zhang Q, Yates MS, Broaddus RR, Slomovitz BM, Lu KH, Coleman RL. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. Clin Cancer Res. 2020 02 01; 26(3):581-587. PMID: 31628143; PMCID: PMC7002216.
      Citations: 11     Fields:    Translation:Humans
    190. Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecol Oncol. 2019 12; 155(3):420-428. PMID: 31623857; PMCID: PMC6922584.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    191. Pishvaian MJ, Blais EM, Bender RJ, Rao S, Boca SM, Chung V, Hendifar AE, Mikhail S, Sohal DPS, Pohlmann PR, Moore KN, He K, Monk BJ, Coleman RL, Herzog TJ, Halverson DD, DeArbeloa P, Petricoin EF, Madhavan S. A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. JAMIA Open. 2019 Dec; 2(4):505-515. PMID: 32025647; PMCID: PMC6994017.
      Citations: 20     
    192. Obermair A, Asher R, Frumovitz M, Ribeiro R, Tsunoda A, Behan V, Buda A, Bernadini MQ, Zhao H, Vieira M, Walker J, Spirtos NM, Yao S, Chetty N, Zhu T, Nicklin J, Robledo KP, Gebski V, Coleman RL, Salvo G, Ramirez PT, Pareja R, Lopez A, Moretti-Marques R, Rendon G, Isla D, Tamura M. Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial. Am J Obstet Gynecol. 2020 03; 222(3):249.e1-249.e10. PMID: 31586602; PMCID: PMC7181470.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    193. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019 12 19; 381(25):2403-2415. PMID: 31562800; PMCID: PMC6941439.
      Citations: 197     Fields:    Translation:HumansCTClinical Trials
    194. Danson S, Mulvey MR, Turner L, Horsman J, Escott K, Coleman RE, Ahmedzai SH, Bennett MI, Andrew D. An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain. J Bone Oncol. 2019 Dec; 19:100261. PMID: 31667062; PMCID: PMC6812043.
      Citations: 6     
    195. Mahtani R, Holmes FA, Badve S, Caldera H, Coleman R, Mamounas E, Kalinsky K, Kittaneh M, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Vogel C, Breast Cancer Therapy Expert Group (BCTEG). A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. Clin Breast Cancer. 2020 06; 20(3):e251-e260. PMID: 32139271.
      Citations: 5     Fields:    Translation:Humans
    196. Webber K, Carolus E, Mileshkin L, Sommeijer D, McAlpine J, Bladgen S, Coleman RL, Herzog TJ, Friedlander M, Sehouli J, Nasser S, Inci G. OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors. Gynecol Oncol. 2019 10; 155(1):126-134. PMID: 31416612.
      Citations: 5     Fields:    Translation:Humans
    197. Lheureux S, Mirza M, Coleman R. The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers. J Clin Oncol. 2019 09 20; 37(27):2449-2459. PMID: 31403862.
      Citations: 3     Fields:    Translation:HumansCells
    198. Vergote I, Coleman RL, Pignata S, Bookman MA, Marth C, Herzog TJ, Gonzalez-Martin A, Copeland LJ, European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation Inc.. Joint ENGOT and GOG Foundation requirements for trials with industry partners. Gynecol Oncol. 2019 08; 154(2):255-258. PMID: 31331494.
      Citations: 1     Fields:    Translation:Humans
    199. Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JMG, Dizon T, Coleman RL, Cole SW, Sood AK. Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecol Oncol. 2019 09; 154(3):524-530. PMID: 31353053; PMCID: PMC6867685.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    200. Vergote I, Coleman RL, Pignata S, Bookman MA, Marth C, Herzog TJ, Gonzalez Martin A, Copeland LJ, European Network of Gynaecological Oncological Trial Groups (ENGOT) and The GOG Foundation, Inc. Joint ENGOT and GOG Foundation requirements for trials with industry partners. Int J Gynecol Cancer. 2019 09; 29(7):1094-1097. PMID: 31320391.
      Citations:    Fields:    Translation:Humans
    201. Chelariu-Raicu A, Coleman RL, Sood AK. Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit? Oncology (Williston Park). 2019 07 16; 33(7). PMID: 31365748.
      Citations: 10     Fields:    Translation:Humans
    202. Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol. 2019 09 10; 37(26):2317-2328. PMID: 31216226; PMCID: PMC6879307.
      Citations: 95     Fields:    Translation:HumansCTClinical Trials
    203. Falchook G, Coleman RL, Schilder RJ. Paclitaxel and Alisertib in Recurrent Ovarian Cancer-In Reply. JAMA Oncol. 2019 06 01; 5(6):910-911. PMID: 31021370.
      Citations: 1     Fields:    Translation:Humans
    204. Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget. 2019 May 28; 10(37):3533-3546. PMID: 31191824; PMCID: PMC6544405.
      Citations: 10     Fields:    
    205. Beaver JA, Coleman RL, Arend RC, Armstrong DK, Bala S, Mills GB, Sood AK, Herzog TJ. Advancing Drug Development in Gynecologic Malignancies. Clin Cancer Res. 2019 08 15; 25(16):4874-4880. PMID: 31126961; PMCID: PMC6697564.
      Citations: 8     Fields:    Translation:Humans
    206. Hinchcliff E, Westin SN, Dal Molin G, LaFargue CJ, Coleman RL. Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies. Int J Gynecol Cancer. 2019 May 22. PMID: 31118216; PMCID: PMC8263126.
      Citations: 1     Fields:    
    207. Halder J, Kamat AA, Landen CN, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy. Clin Cancer Res. 2019 May 15; 25(10):3194. PMID: 31092618.
      Citations: 1     Fields:    
    208. Sestak I, Blake GM, Patel R, Coleman RE, Cuzick J, Eastell R. Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. Bone. 2019 07; 124:83-88. PMID: 31028957; PMCID: PMC6548284.
      Citations: 2     Fields:    Translation:Humans
    209. Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK. GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther. 2019 05; 18(5):969-979. PMID: 30926640; PMCID: PMC6497555.
      Citations: 3     Fields:    Translation:HumansAnimals
    210. Kurnit KC, Westin SN, Coleman RL. Microsatellite instability in endometrial cancer: New purpose for an old test. Cancer. 2019 07 01; 125(13):2154-2163. PMID: 30913308; PMCID: PMC6763363.
      Citations: 3     Fields:    Translation:Humans
    211. Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA. Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019 04; 20(4):570-580. PMID: 30880072; PMCID: PMC7025391.
      Citations: 69     Fields:    Translation:HumansCTClinical Trials
    212. Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. 2019 06 15; 125(12):1963-1972. PMID: 30835824; PMCID: PMC6557260.
      Citations: 17     Fields:    Translation:Humans
    213. Naumann RW, Coleman RL, Brown J, Moore KN. Phase III trials in ovarian cancer: The evolving landscape of front line therapy. Gynecol Oncol. 2019 05; 153(2):436-444. PMID: 30765149.
      Citations: 9     Fields:    Translation:Humans
    214. Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, Liu Y, Zhou X, Zhang T, Gong C, Wei X, Liu D, Sun C, Chen G, Hu J, Meng L, Zhou J, Sawada K, Fruscio R, Grunt TW, Pothuri B, Coleman RL, Wischhusen J, Vargas-Hern?ndez VM. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J Exp Med. 2019 03 04; 216(3):688-703. PMID: 30710055; PMCID: PMC6400537.
      Citations: 58     Fields:    Translation:HumansAnimalsCells
    215. Westbrook JA, Wood SL, Cairns DA, McMahon K, Gahlaut R, Thygesen H, Shires M, Roberts S, Marshall H, Oliva MR, Dunning MJ, Hanby AM, Selby PJ, Speirs V, Mavria G, Coleman RE, Brown JE. Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. J Pathol. 2019 03; 247(3):381-391. PMID: 30426503; PMCID: PMC6618075.
      Citations: 19     Fields:    Translation:HumansCells
    216. Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X, Bradbury SMJ, Hambley L, Cookson V, Allocca G, Kruithof de Julio M, Coleman RE, Brown JE, Holen I, Ottewell PD. Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment. Clin Cancer Res. 2019 05 01; 25(9):2769-2782. PMID: 30670488.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    217. Uccella S, Coleman RL, Fagotti A, Zannoni GF. Presumed early ovarian cancer with isolated tumor cells in para-aortic sentinel nodes. Int J Gynecol Cancer. 2019 01; 29(1):216-220. PMID: 30640707.
      Citations: 2     Fields:    Translation:Humans
    218. Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ, Ray-Coquard I. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):e183773. PMID: 30347019; PMCID: PMC6439781.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    219. LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019 01; 20(1):e15-e28. PMID: 30614472; PMCID: PMC7292736.
      Citations: 74     Fields:    Translation:Humans
    220. Armbruster S, Coleman RL, Rauh-Hain JA. Management and Treatment of Recurrent Epithelial Ovarian Cancer. Hematol Oncol Clin North Am. 2018 12; 32(6):965-982. PMID: 30390768.
      Citations: 16     Fields:    Translation:Humans
    221. Slomovitz BM, Taub MC, Huang M, Levenback C, Coleman RL. A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS). Gynecol Oncol Rep. 2019 Feb; 27:1-4. PMID: 30519622; PMCID: PMC6260388.
      Citations: 4     
    222. Kurnit KC, Coleman RL, Westin SN. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. Curr Treat Options Oncol. 2018 11 15; 19(12):1. PMID: 30535808; PMCID: PMC8240125.
      Citations: 14     Fields:    Translation:Humans
    223. Lin KK, Harrell MI, Oza AM, Oaknin A, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM, Ray-Coquard I. BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov. 2019 02; 9(2):210-219. PMID: 30425037.
      Citations: 89     Fields:    Translation:HumansCTClinical Trials
    224. Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KA. Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. JAMA Oncol. 2018 11 01; 4(11):1519-1526. PMID: 29860375; PMCID: PMC6248088.
      Citations: 14     Fields:    Translation:Humans
    225. Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, Buda A, Yan X, Shuzhong Y, Chetty N, Isla D, Tamura M, Zhu T, Robledo KP, Gebski V, Asher R, Behan V, Nicklin JL, Coleman RL, Obermair A. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med. 2018 Nov 15; 379(20):1895-1904. PMID: 30380365.
      Citations: 329     Fields:    Translation:HumansCTClinical Trials
    226. Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol. 2018 12; 151(3):428-432. PMID: 30366647; PMCID: PMC6281799.
      Citations: 4     Fields:    Translation:Humans
    227. Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK. When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer. 2018 10; 28(8):1485-1490. PMID: 30036226; PMCID: PMC6355335.
      Citations: 2     Fields:    Translation:Humans
    228. Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380. PMID: 30213435; PMCID: PMC6235625.
      Citations:    Fields:    Translation:Humans
    229. Richardson DL, Coleman RL, Sill MW. Paclitaxel and Pazopanib in Ovarian Cancer-Reply. JAMA Oncol. 2018 09 01; 4(9):1299. PMID: 29978183.
      Citations: 2     Fields:    Translation:Humans
    230. Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018 09; 132(3):545-554. PMID: 30095787; PMCID: PMC6105510.
      Citations: 17     Fields:    Translation:Humans
    231. Handforth C, Burkinshaw R, Freeman J, Brown JE, Snowden JA, Coleman RE, Greenfield DM. Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer. Support Care Cancer. 2019 May; 27(5):1755-1763. PMID: 30143894.
      Citations: 1     Fields:    Translation:Humans
    232. Zibetti Dal Molin G, Coleman RL, Abrah?o CM, Maluf FC. Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma. Gynecol Oncol Res Pract. 2018; 5:6. PMID: 30147940; PMCID: PMC6098839.
      Citations: 2     
    233. Nishio S, Matsuo K, Yonemoto K, Shimokawa M, Hosaka M, Kodama M, Miyake TM, Ushijima K, Kamura T, Westin SN, Soliman PT, Coleman RL. Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer. Oncotarget. 2018 Aug 17; 9(64):32321-32330. PMID: 30190789; PMCID: PMC6122357.
      Citations: 3     Fields:    
    234. Dal Molin GZ, Westin SN, Coleman RL. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease. Future Oncol. 2018 Dec; 14(30):3101-3110. PMID: 30105925; PMCID: PMC6331693.
      Citations: 4     Fields:    Translation:Humans
    235. Brown J, Rathbone E, Hinsley S, Gregory W, Gossiel F, Marshall H, Burkinshaw R, Shulver H, Thandar H, Bertelli G, Maccon K, Bowman A, Hanby A, Bell R, Cameron D, Coleman R. Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. J Natl Cancer Inst. 2018 08 01; 110(8):871-879. PMID: 29425304; PMCID: PMC6093369.
      Citations: 15     Fields:    Translation:Humans
    236. Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Hutchinson JN, Haider MT, Rhee CS, Qin Y, Gregory WM, Garrido-Castro AC, Holen I, Brown JE, Coleman RE, Scadden DT, McAllister SS. Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer. Cancer Res. 2018 09 15; 78(18):5300-5314. PMID: 30065048; PMCID: PMC6309204.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    237. Dal Molin GZ, Omatsu K, Sood AK, Coleman RL. Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. Ther Adv Med Oncol. 2018; 10:1758835918778483. PMID: 29977351; PMCID: PMC6024342.
      Citations: 10     
    238. Chan JK, Chow S, Bhowmik S, Mann A, Kapp DS, Coleman RL. Metastatic gynecologic malignancies: advances in treatment and management. Clin Exp Metastasis. 2018 08; 35(5-6):521-533. PMID: 29931499.
      Citations: 6     Fields:    Translation:Humans
    239. Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Tondini C, Ciruelos E, Burstein HJ, Bellet M, Martino S, Geyer CE, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM, SOFT and TEXT Investigators and the International Breast Cancer Study Group, L?ng I, G?mez HL, Bonnefoi HR. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137. PMID: 29863451; PMCID: PMC6193457.
      Citations: 131     Fields:    Translation:Humans
    240. Abraham J, Coleman R, Elias A, Holmes FA, Kalinsky K, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Vogel C, Breast Cancer Therapy Expert Group (BCTEG). Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Breast Cancer Res Treat. 2018 Aug; 171(1):11-20. PMID: 29725889.
      Citations: 13     Fields:    Translation:HumansAnimals
    241. Brown J, Naumann RW, Brady WE, Coleman RL, Moore KN, Gershenson DM. Clinical trial methodology in rare gynecologic tumor research: Strategies for success. Gynecol Oncol. 2018 06; 149(3):605-611. PMID: 29699802.
      Citations: 2     Fields:    Translation:Humans
    242. Ma S, Pradeep S, Hu W, Zhang D, Coleman R, Sood A. The role of tumor microenvironment in resistance to anti-angiogenic therapy. F1000Res. 2018; 7:326. PMID: 29560266; PMCID: PMC5854986.
      Citations: 21     Fields:    
    243. Logothetis C, Morris MJ, Den R, Coleman RE. Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer Metastasis Rev. 2018 03; 37(1):189-196. PMID: 29380085; PMCID: PMC5801387.
      Citations: 29     Fields:    Translation:HumansAnimals
    244. Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, Aghajanian C. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):196-202. PMID: 29242937; PMCID: PMC5838582.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    245. Squires H, Pandor A, Thokala P, Stevens JW, Kaltenthaler E, Clowes M, Coleman R, Wyld L. Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2018 01; 36(1):29-38. PMID: 28770452.
      Citations: 6     Fields:    Translation:Humans
    246. Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs RA, Nagaraja AS, McGuire M, Jennings NB, Broaddus R, Coleman RL, Sood AK. Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther. 2018 02; 17(2):464-473. PMID: 29237804; PMCID: PMC5805630.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    247. Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, Nagaraja AS, Haemmerle M, Mak CSL, Chen X, Gharpure KM, Deng H, Xiong W, Kingsley CV, Liu J, Jennings N, Birrer MJ, Bouchard RR, Lopez-Berestein G, Coleman RL, An Z, Sood AK. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep. 2017 Dec 05; 21(10):2785-2795. PMID: 29212026; PMCID: PMC5749980.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    248. Le TN, Harvey RE, Kim CK, Brown J, Coleman RL, Smith JA. A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer. Gynecol Oncol Res Pract. 2017; 4:16. PMID: 29158911; PMCID: PMC5684736.
      Citations: 3     
    249. Niu H, Shin H, Gao F, Zhang J, Bahamon B, Danaee H, Melichar B, Schilder RJ, Coleman RL, Falchook G, Adenis A, Behbakht K, DeMichele A, Dees EC, Perez K, Matulonis U, Sawrycki P, Huebner D, Ecsedy J. Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor. EBioMedicine. 2017 Nov; 25:50-57. PMID: 29122619; PMCID: PMC5704062.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    250. Coleman R, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Tercero JC, Gregory W, Jean-Mairet J, Rojo F, Gomis RR. Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. Lancet Oncol. 2017 11; 18(11):1543-1552. PMID: 29037984.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    251. Coleman RE, Janni W, Baselga J, Cort?s J. Advances in the management of HER2-positive early breast cancer. Crit Rev Oncol Hematol. 2017 Nov; 119:113-122. PMID: 29042085; PMCID: PMC5662944.
      Citations: 18     Fields:    Translation:Humans
    252. Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Holloway RW, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Swisher EM, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA, ARIEL3 investigators, Scambia G, Leary A, Gancedo MA, Garcia-Donas J, Floquet A. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Oct 28; 390(10106):1949-1961. PMID: 28916367; PMCID: PMC5901715.
      Citations: 453     Fields:    Translation:HumansCTClinical Trials
    253. Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS, Ray-Coquard I, Provencher D. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017 11; 147(2):267-275. PMID: 28882436.
      Citations: 83     Fields:    Translation:HumansCTClinical Trials
    254. Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res. 2017 Nov 15; 23(22):7034-7046. PMID: 28855350; PMCID: PMC5690831.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    255. Herzog TJ, Ison G, Alvarez RD, Balasubramaniam S, Armstrong DK, Beaver JA, Ellis A, Tang S, Ford P, McKee A, Gershenson DM, Kim G, Monk BJ, Pazdur R, Coleman RL. FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper. Gynecol Oncol. 2017 10; 147(1):3-10. PMID: 28844539.
      Citations: 9     Fields:    Translation:Humans
    256. Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017 Nov 14; 8(57):96496-96505. PMID: 29228548; PMCID: PMC5722500.
      Citations: 24     Fields:    
    257. Fleming ND, Coleman RL, Tung C, Westin SN, Hu W, Sun Y, Bhosale P, Munsell MF, Sood AK. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol. 2017 10; 147(1):41-46. PMID: 28774461; PMCID: PMC5605462.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    258. Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Helle SI, O'Sullivan JM, Wiechno P, Logue J, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Petrenciuc O, Staudacher K, Li R, Nilsson S, Heinrich D, Foss? SD, Chodacki A, Seke M, Widmark A, Johannessen DC, Dall'Oglio M, Franz?n L, Bruland ?S. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. Eur Urol. 2018 Mar; 73(3):427-435. PMID: 28705540.
      Citations: 30     Fields:    
    259. D'Oronzo S, Brown J, Coleman R. The value of biomarkers in bone metastasis. Eur J Cancer Care (Engl). 2017 Nov; 26(6). PMID: 28653449.
      Citations: 18     Fields:    Translation:HumansCells
    260. Randall LM, Pothuri B, Swisher EM, Diaz JP, Buchanan A, Witkop CT, Bethan Powell C, Smith EB, Robson ME, Boyd J, Coleman RL, Lu K. Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper. Gynecol Oncol. 2017 08; 146(2):217-224. PMID: 28596016.
      Citations: 29     Fields:    Translation:Humans
    261. Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D, Brunt AM, Earl H, Ellis P, Gaunt C, Gillman A, Hearfield N, Laing R, Murray N, Couper N, Stein RC, Verrill M, Wardley A, Barrett-Lee P, Bliss JM, TACT2 Investigators. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2017 07; 18(7):929-945. PMID: 28600210; PMCID: PMC5489700.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    262. Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Friedlander M, Kichenadasse G, O'Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin KK, Scott CL, AOCS Study Group, Floquet A. Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov. 2017 09; 7(9):984-998. PMID: 28588062; PMCID: PMC5612362.
      Citations: 122     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    263. Earl HM, Hiller L, Howard HC, Dunn JA, Young J, Bowden SJ, McDermaid M, Waterhouse AK, Wilson G, Agrawal R, O'Reilly S, Bowman A, Ritchie DM, Goodman A, Hickish T, McAdam K, Cameron D, Dodwell D, Rea DW, Caldas C, Provenzano E, Abraham JE, Canney P, Crown JP, Kennedy MJ, Coleman R, Leonard RC, Carmichael JA, Wardley AM, Poole CJ, tAnGo trial collaborators. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017 06; 18(6):755-769. PMID: 28479233.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    264. Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, L?nning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC. Long-Term Follow-Up of the Intergroup Exemestane Study. J Clin Oncol. 2017 Aug 01; 35(22):2507-2514. PMID: 28467729; PMCID: PMC6175047.
      Citations: 5     Fields:    Translation:Humans
    265. Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 06; 18(6):779-791. PMID: 28438473; PMCID: PMC5715461.
      Citations: 155     Fields:    Translation:HumansCTClinical Trials
    266. Wagner MJ, Mitra R, McArthur MJ, Baze W, Barnhart K, Wu SY, Rodriguez-Aguayo C, Zhang X, Coleman RL, Lopez-Berestein G, Sood AK. Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Mol Cancer Ther. 2017 06; 16(6):1114-1123. PMID: 28265009; PMCID: PMC5457703.
      Citations: 33     Fields:    Translation:HumansAnimals
    267. Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol. 2017 Apr 01; 35(10):1103-1111. PMID: 28221866; PMCID: PMC5455356.
      Citations: 39     Fields:    Translation:Humans
    268. Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, Iasonos A, Denesopolis J, Zivanovic O, Long Roche KC, Sonoda Y, Coleman RL, Abu-Rustum NR, Hricak H, Chi DS. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecol Oncol. 2017 Apr; 145(1):27-31. PMID: 28209497; PMCID: PMC5387995.
      Citations: 30     Fields:    Translation:Humans
    269. Ng CS, Zhang Z, Lee SI, Marques HS, Burgers K, Su F, Bauza J, Mannel RS, Walker JL, Huh WK, Rubin SC, DiSilvestro P, Martin LP, Chan JK, Bookman MA, Coleman RL, Lee TY. CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. Clin Cancer Res. 2017 Jul 15; 23(14):3684-3691. PMID: 28174234; PMCID: PMC5720368.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    270. Westin SN, Coleman RL. Individualized Medicine in Ovarian Cancer: Are We There Yet? Gynecol Oncol. 2017 02; 144(2):229-231. PMID: 28089051; PMCID: PMC5881923.
      Citations:    Fields:    Translation:Humans
    271. Smith JA, Mathew L, Burney M, Nyshadham P, Coleman RL. Corrigendum to 'Equivalency challenge: evaluation of Lipodox? as the generic equivalent for Doxil? in a human ovarian cancer orthotropic mouse model' [Gynecol. Oncol. 141 (2016) 357-363]. Gynecol Oncol. 2017 02; 144(2):448. PMID: 28089052.
      Citations: 1     Fields:    
    272. Coleman RA, Liang C, Patel R, Ali S, Mukherjee J. Brain and Brown Adipose Tissue Metabolism in Transgenic Tg2576 Mice Models of Alzheimer Disease Assessed Using 18F-FDG PET Imaging. Mol Imaging. 2017 01 01; 16:1536012117704557. PMID: 28654383; PMCID: PMC5470140.
      Citations: 14     Fields:    Translation:Animals
    273. Parker C, Zhan L, Cislo P, Reuning-Scherer J, Vogelzang NJ, Nilsson S, Sartor O, O'Sullivan JM, Coleman RE. Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. Eur J Cancer. 2017 01; 71:1-6. PMID: 27930924.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    274. Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Harrell MI, Mann E, Kaufmann SH, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA, Ray-Coquard I, Floquet A. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017 01; 18(1):75-87. PMID: 27908594.
      Citations: 386     Fields:    Translation:HumansCTClinical Trials
    275. Holen I, Lefley DV, Francis SE, Rennicks S, Bradbury S, Coleman RE, Ottewell P. IL-1 drives breast cancer growth and bone metastasis in vivo. Oncotarget. 2016 Nov 15; 7(46):75571-75584. PMID: 27765923; PMCID: PMC5342762.
      Citations: 90     Fields:    Translation:HumansAnimalsCells
    276. Liu JF, Ray-Coquard I, Selle F, Poveda AM, Cibula D, Hirte H, Hilpert F, Raspagliesi F, Gladieff L, Harter P, Siena S, Del Campo JM, Tabah-Fisch I, Pearlberg J, Moyo V, Riahi K, Nering R, Kubasek W, Adiwijaya B, Czibere A, Naumann RW, Coleman RL, Vergote I, MacBeath G, Pujade-Lauraine E. Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. J Clin Oncol. 2016 12 20; 34(36):4345-4353. PMID: 27998236; PMCID: PMC5562430.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    277. Monk BJ, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Karlan BY, Richardson G, Coleman RL, Brize A, Fabbro M, Bamias A, Ma H, Vogl FD, Bach BA, Oza AM, Poveda A, Ray-Coquard I, Provencher DM, Lhomm? C, Rinc?n DG, Marth C, Redondo A. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol. 2016 Oct; 143(1):27-34. PMID: 27546885.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    278. Vogelzang NJ, Coleman RE, Michalski JM, Nilsson S, O'Sullivan JM, Parker C, Thuresson M, Xu L, Germino J, Sartor O, Widmark A. Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. Clin Genitourin Cancer. 2017 02; 15(1):42-52.e8. PMID: 27613490.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    279. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 10 01; 34(28):3460-73. PMID: 27502591; PMCID: PMC5512594.
      Citations: 93     Fields:    Translation:Humans
    280. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol. 2016 10; 143(1):3-15. PMID: 27650684; PMCID: PMC5413203.
      Citations: 63     Fields:    Translation:Humans
    281. Frumovitz M, Burzawa JK, Byers LA, Lyons YA, Ramalingam P, Coleman RL, Brown J. Corrigendum to "Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer" [Gynecol. Oncol. 141 (2016) 588-591]. Gynecol Oncol. 2016 10; 143(1):224. PMID: 27477189; PMCID: PMC5124488.
      Citations:    Fields:    
    282. Coleman RL, Monk BJ. Saving the best treatment for last? Ann Oncol. 2016 09; 27(9):1656-8. PMID: 27456298.
      Citations:    Fields:    
    283. Randall TC, Denny L, Johnston CM, Schmeler KM, Covens AL, Cibula D, Bookman MA, Rawal S, DePetrillo D, Nam JH, Goodman A, Naik R, Manchanda R, Gaffney DK, Small W, Creutzberg C, Rattray C, Kesic V, Eiken M, Belleson K, Coleman RL, Barakat RR, Trimble EL, Quinn M, Chuang LT, Paraja R. Sister Society Meeting on Global Education Development and Collaboration: Meeting Report. Int J Gynecol Cancer. 2016 07; 26(6):1186-8. PMID: 27327155.
      Citations: 6     Fields:    Translation:Humans
    284. Parker C, Finkelstein SE, Michalski JM, O'Sullivan JM, Vogelzang NJ, Coleman RE, Nilsson S, Sartor O, Li R, Seger MA, Bottomley D, Bruland ?. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. Eur Urol. 2016 11; 70(5):875-883. PMID: 27344296.
      Citations: 21     Fields:    Translation:Humans
    285. Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43. PMID: 27147567; PMCID: PMC5085215.
      Citations: 6     Fields:    Translation:Humans
    286. Coleman RL. Foreword. Gynecol Oncol. 2016 06; 141 Suppl 1:1. PMID: 27267443.
      Citations:    Fields:    Translation:Humans
    287. Meyer L, Suidan R, Sun C, Westin S, Coleman RL, Mills GB. The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer. Expert Rev Qual Life Cancer Care. 2016; 1(3):231-238. PMID: 30906877; PMCID: PMC6425954.
      Citations: 6     
    288. Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2016 07 01; 34(19):2279-86. PMID: 27217446; PMCID: PMC4962710.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    289. Takekuma M, Wong KK, Coleman RL. A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib. Gynecol Oncol Res Pract. 2016; 3:5. PMID: 27231576; PMCID: PMC4880811.
      Citations: 8     
    290. Salvo G, Mehran R, Sood AK, Coleman RL, Lu KH, Vaporciyan A, Ramirez PT, Di Guilmi J. Role of Video-Assisted Thoracoscopy in Advanced Ovarian Cancer: A Literature Review. Int J Gynecol Cancer. 2016 May; 26(4):801-6. PMID: 26937753.
      Citations: 2     Fields:    Translation:Humans
    291. Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol. 2016 Jun; 12(12):1439-56. PMID: 27087632; PMCID: PMC4976841.
      Citations: 26     Fields:    Translation:Humans
    292. Frumovitz M, Burzawa JK, Byers LA, Lyons YA, Ramalingam P, Coleman RL, Brown J. Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer. Gynecol Oncol. 2016 06; 141(3):588-591. PMID: 27079212; PMCID: PMC4877250.
      Citations: 17     Fields:    Translation:Humans
    293. Alvarez RD, Matulonis UA, Herzog TJ, Coleman RL, Monk BJ, Markman M. Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer. Gynecol Oncol. 2016 06; 141(3):405-409. PMID: 27049967.
      Citations: 9     Fields:    Translation:Humans
    294. Wilson C, Coleman R. Adjuvant Bone-Targeted Therapies for Postmenopausal Breast Cancer. JAMA Oncol. 2016 Apr; 2(4):423-4. PMID: 26794938.
      Citations: 2     Fields:    Translation:Humans
    295. Coleman RL, Matulonis UA. Precision medicine. Gynecol Oncol. 2016 Apr; 141(1):1. PMID: 27016221.
      Citations: 2     Fields:    Translation:Humans
    296. Sartor O, Hoskin P, Coleman RE, Nilsson S, Vogelzang NJ, Petrenciuc O, Staudacher K, Thuresson M, Parker C. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. Prostate. 2016 07; 76(10):905-16. PMID: 27004570; PMCID: PMC5071661.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    297. Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Mol Cancer Ther. 2016 06; 15(6):1344-52. PMID: 27009216; PMCID: PMC4893925.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    298. Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol Oncol. 2016 May; 141(2):260-263. PMID: 26968641; PMCID: PMC4844793.
      Citations: 26     Fields:    Translation:Humans
    299. Coleman RL, Herzog TJ, Chan DW, Munroe DG, Pappas TC, Smith A, Zhang Z, Wolf J. Validation of a second-generation multivariate index assay for?malignancy risk of adnexal masses. Am J Obstet Gynecol. 2016 Jul; 215(1):82.e1-82.e11. PMID: 26970494.
      Citations: 36     Fields:    Translation:Humans
    300. Smith JA, Mathew L, Burney M, Nyshadham P, Coleman RL. Equivalency challenge: Evaluation of Lipodox? as the generic equivalent for Doxil? in a human ovarian cancer orthotropic mouse model. Gynecol Oncol. 2016 05; 141(2):357-363. PMID: 26946092.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    301. Hansen JM, Coleman RL, Sood AK. Targeting the tumour microenvironment in ovarian cancer. Eur J Cancer. 2016 Mar; 56:131-143. PMID: 26849037; PMCID: PMC4769921.
      Citations: 54     Fields:    Translation:HumansAnimalsCells
    302. Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N, Gl?ck S. Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 2016 Feb 03; 17:63. PMID: 26841937; PMCID: PMC4739389.
      Citations:    Fields:    
    303. Gregory WM, Twelves CJ, Bell R, Smye SW, Howard DR, Coleman RE, Cameron DA. Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling. Breast Cancer Res Treat. 2016 Jan; 155(2):303-11. PMID: 26783036; PMCID: PMC4729810.
      Citations:    Fields:    Translation:Humans
    304. Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE, Selby PJ, Coleman RE, Brown JE. CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. J Natl Cancer Inst. 2016 Apr; 108(4). PMID: 26757732; PMCID: PMC4808632.
      Citations: 36     Fields:    Translation:HumansCells
    305. Coleman RL. Ovarian cancer in 2015: Insights into strategies for optimizing ovarian cancer care. Nat Rev Clin Oncol. 2016 Feb; 13(2):71-2. PMID: 26718108.
      Citations: 9     Fields:    Translation:Humans
    306. Coleman R, Hadji P, Schmidt N, Jacob L, Kostev K. The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. Breast Cancer Res Treat. 2016 01; 155(1):151-7. PMID: 26687384.
      Citations: 9     Fields:    Translation:Humans
    307. Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N, Gl?ck S. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 2015 Dec 16; 16:575. PMID: 26673577; PMCID: PMC4682258.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    308. Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J, IBIS-II investigators, Levy C. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016 Feb 27; 387(10021):866-73. PMID: 26686313; PMCID: PMC4769326.
      Citations: 39     Fields:    Translation:Humans
    309. Minion LE, Coleman RL, Alvarez RD, Herzog TJ. Endpoints in clinical trials: What do patients consider important? A survey of the Ovarian Cancer National Alliance. Gynecol Oncol. 2016 Feb; 140(2):193-8. PMID: 26631607.
      Citations: 16     Fields:    Translation:Humans
    310. Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. Mol Cancer Ther. 2015 Dec; 14(12):2677-86. PMID: 26516159; PMCID: PMC4674355.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    311. Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK, Armaiz-Pe?a GN. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 2015 Nov 09; 28(5):610-622. PMID: 26481148; PMCID: PMC4643364.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    312. Pavlovic M, Arnal-Estap? A, Rojo F, Bellmunt A, Tarragona M, Guiu M, Planet E, Garcia-Alb?niz X, Morales M, Urosevic J, Gawrzak S, Rovira A, Prat A, Nonell L, Lluch A, Jean-Mairet J, Coleman R, Albanell J, Gomis RR. Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. J Natl Cancer Inst. 2015 Dec; 107(12):djv256. PMID: 26376684; PMCID: PMC4681582.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    313. Castro MP, Whitcomb BP, Zajchowski DA, Coleman RL. Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease. Gynecol Oncol Res Pract. 2015; 2:4. PMID: 27231564; PMCID: PMC4880882.
      Citations: 4     
    314. Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, Matsuo K, Squires KC, Coleman RL, Lutgendorf SK, Ramirez PT, Sood AK. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. 2015 Oct 01; 121(19):3444-51. PMID: 26301456; PMCID: PMC4575637.
      Citations: 85     Fields:    Translation:Humans
    315. Slomovitz BM, Coleman RL. Reply to G. Bogani et al. J Clin Oncol. 2015 Oct 20; 33(30):3516. PMID: 26240222.
      Citations:    Fields:    Translation:Humans
    316. Smith JA, Costales AB, Jaffari M, Urbauer DL, Frumovitz M, Kutac CK, Tran H, Coleman RL. Is it equivalent? Evaluation of the clinical activity of single agent Lipodox? compared to single agent Doxil? in ovarian cancer treatment. J Oncol Pharm Pract. 2016 Aug; 22(4):599-604. PMID: 26183293.
      Citations: 6     Fields:    Translation:Humans
    317. Graybill W, Sood AK, Monk BJ, Coleman RL. State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. Gynecol Oncol. 2015 Aug; 138(2):223-6. PMID: 26166806.
      Citations: 14     Fields:    Translation:Humans
    318. Graham JD, Powell MA, Fujiwara K, Herzog TJ, Coleman RL, Clarke CL, Gilles EM, Zukiwski AA, Monk BJ, Bonneterre J, Hutt E, Bosq J, Leblanc E. Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus. Gynecol Oncol. 2015 Sep; 138(3):663-7. PMID: 26142884.
      Citations: 5     Fields:    Translation:Humans
    319. Previs R, Leath CA, Coleman RL, Herzog TJ, Krivak TC, Brower SL, Tian C, Secord AA. Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. Gynecol Oncol. 2015 Aug; 138(2):267-71. PMID: 26037898.
      Citations: 7     Fields:    Translation:Humans
    320. Slomovitz BM, Coleman RL, Oonk MH, van der Zee A, Levenback C. Update on sentinel lymph node biopsy for early-stage vulvar cancer. Gynecol Oncol. 2015 Aug; 138(2):472-7. PMID: 26022527.
      Citations: 10     Fields:    Translation:Humans
    321. Westin SN, Ju Z, Broaddus RR, Krakstad C, Li J, Pal N, Lu KH, Coleman RL, Hennessy BT, Klempner SJ, Werner HM, Salvesen HB, Cantley LC, Mills GB, Myers AP. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol. 2015 Oct; 9(8):1694-703. PMID: 26045339; PMCID: PMC4584169.
      Citations: 21     Fields:    Translation:HumansCells
    322. Coleman R, King T, Nicoara CD, Bader M, McCarthy L, Chandran H, Parashar K. Combined creatinine velocity and nadir creatinine: A reliable predictor of renal outcome in neonatally diagnosed posterior urethral valves. J Pediatr Urol. 2015 Aug; 11(4):214.e1-3. PMID: 26062970.
      Citations: 2     Fields:    Translation:Humans
    323. Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MS, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, Liu T, Shacham S, McCauley D, Hawke DH, Wiktorowicz JE, Coleman RL, Sood AK. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clin Cancer Res. 2015 Jul 15; 21(14):3286-97. PMID: 25878333; PMCID: PMC4506247.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    324. Coleman RL, Sill MW, Thaker PH, Bender DP, Street D, McGuire WP, Johnston CM, Rotmensch J. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jul; 138(1):30-5. PMID: 25887099; PMCID: PMC4469526.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    325. Thanapprapasr D, Previs RA, Hu W, Ivan C, Armaiz-Pena GN, Dorniak PL, Hansen JM, Rupaimoole R, Huang J, Dalton HJ, Ali-Fehmi R, Coleman RL, Sood AK. PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Mol Cancer Ther. 2015 Jun; 14(6):1466-1475. PMID: 25833835; PMCID: PMC4458384.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    326. Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, Ramirez PT, G?mez-Hidalgo NR. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol. 2015 Jun; 137(3):553-8. PMID: 25827290; PMCID: PMC4825172.
      Citations: 24     Fields:    Translation:Humans
    327. Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jun; 137(3):386-91. PMID: 25818403; PMCID: PMC4447525.
      Citations: 98     Fields:    Translation:HumansCTClinical Trials
    328. Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S, Shepherd LE, Dent S, Ellard SL, Tonkin K, Pritchard KI, Whelan TJ, Nomikos D, Nusch A, Coleman RE, Mukai H, Tjulandin S, Khasanov R, Rizel S, Connor AP, Santillana SL, Chapman JA, Parulekar WR. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. J Clin Oncol. 2015 May 10; 33(14):1574-83. PMID: 25779558.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    329. Secord AA, Coleman RL, Havrilesky LJ, Abernethy AP, Samsa GP, Cella D. Patient-reported outcomes as end points and outcome indicators in solid tumours. Nat Rev Clin Oncol. 2015 Jun; 12(6):358-70. PMID: 25754949.
      Citations: 20     Fields:    Translation:Humans
    330. Herzog TJ, Coleman RL, Monk BJ, Armstrong DK, Alvarez RD. In assessing surrogate clinical trial end points: drug safety is a requisite. J Clin Oncol. 2015 May 01; 33(13):1511-2. PMID: 25732164.
      Citations:    Fields:    Translation:Humans
    331. Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev. 2015 Mar; 34(1):19-40. PMID: 25544368; PMCID: PMC4369424.
      Citations: 44     Fields:    Translation:HumansCells
    332. Vergote IB, Marth C, Coleman RL. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev. 2015 Mar; 34(1):41-52. PMID: 25564455.
      Citations: 47     Fields:    Translation:Humans
    333. Nick AM, Coleman RL, Ramirez PT, Sood AK. A framework for a personalized surgical approach to ovarian cancer. Nat Rev Clin Oncol. 2015 Apr; 12(4):239-45. PMID: 25707631; PMCID: PMC4528308.
      Citations: 68     Fields:    Translation:Humans
    334. Wilson C, Ottewell P, Coleman RE, Holen I. The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway. BMC Cancer. 2015 Feb 14; 15:55. PMID: 25884855; PMCID: PMC4329195.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    335. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015 Jun 29; 87:108-19. PMID: 25666164; PMCID: PMC4504743.
      Citations: 132     Fields:    Translation:HumansAnimals
    336. Yang X, Shen F, Hu W, Coleman RL, Sood AK. New ways to successfully target tumor vasculature in ovarian cancer. Curr Opin Obstet Gynecol. 2015 Feb; 27(1):58-65. PMID: 25502429; PMCID: PMC4529067.
      Citations: 6     Fields:    Translation:Humans
    337. Vari F, Radford KJ, Tong H, Hardy MY, D'Rozario R, Waterhouse NJ, Rossetti T, Coleman R, Tracey C, Goossen H, Gounder V, Crosbie G, Hancock S, Diaz-Guilas S, Mainwaring P, Swindle P, Hart DN, Prue RL. A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer. J Immunother. 2015 Feb-Mar; 38(2):71-6. PMID: 25658616.
      Citations: 51     Fields:    Translation:HumansCellsCTClinical Trials
    338. Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, Levenback C, Zhang Q, Ring K, Munsell MF, Gershenson DM, Lu KH, Coleman RL. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015 Mar 10; 33(8):930-6. PMID: 25624430; PMCID: PMC4348638.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    339. Francis PA, Regan MM, Fleming GF, Ciruelos E, Bellet M, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD, SOFT Investigators, International Breast Cancer Study Group, L?ng I, Bonnefoi HR. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29; 372(5):436-46. PMID: 25495490; PMCID: PMC4341825.
      Citations: 190     Fields:    Translation:HumansCTClinical Trials
    340. Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, Kurzrock R, Fu S. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget. 2014 Nov 30; 5(22):11168-79. PMID: 25426553; PMCID: PMC4294378.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    341. Kelley JL, Chan JK, Krivak TC, Powell MA, Rutherford TJ, Coleman RL, Plamadeala V, Gabrin MJ, Brower SL. A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer. Gynecol Oncol. 2015 Jan; 136(1):94-8. PMID: 25462203.
      Citations: 6     Fields:    Translation:Humans
    342. Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res. 2015 Jan 15; 21(2):448-59. PMID: 25416196; PMCID: PMC4297546.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    343. Previs RA, Coleman RL, Harris AL, Sood AK. Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res. 2015 Mar 01; 21(5):955-61. PMID: 25388163; PMCID: PMC4333206.
      Citations: 67     Fields:    Translation:HumansAnimalsCells
    344. Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, Coleman R, Dowsett M, Forbes JF, Howell A, Eastell R. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2014 Dec; 15(13):1460-1468. PMID: 25456365.
      Citations: 17     Fields:    Translation:Humans
    345. Coleman RL, Herzog TJ, Monk BJ, Dooner P. Gynecologic Oncology Research and Practice: a new journal to meet the needs of a growing field. Gynecol Oncol Res Pract. 2014; 1:1. PMID: 27231554; PMCID: PMC4878069.
      Citations:    
    346. Goyal A, Dodwell D, Reed MW, Coleman RE. Axillary treatment in women with one or two sentinel nodes with macrometastases: more evidence is needed to inform practice. J Clin Oncol. 2014 Dec 01; 32(34):3902. PMID: 25245444.
      Citations: 7     Fields:    Translation:Humans
    347. Herzog TJ, Alvarez RD, Secord A, Goff BA, Mannel RS, Monk BJ, Coleman RL. SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm. Gynecol Oncol. 2014 Oct; 135(1):3-7. PMID: 25124162; PMCID: PMC4698962.
      Citations: 3     Fields:    Translation:Humans
    348. Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Burkinshaw R, Grieve R, Barrett-Lee P, Ritchie D, Liversedge V, Hinsley S, Marshall H, AZURE investigators, Gil M. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 2014 Aug; 15(9):997-1006. PMID: 25035292.
      Citations: 105     Fields:    Translation:HumansCTClinical Trials
    349. Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014 Jul 14; 26(1):77-91. PMID: 25026212; PMCID: PMC4100212.
      Citations: 142     Fields:    Translation:HumansAnimalsCells
    350. Tian C, Sargent DJ, Krivak TC, Powell MA, Gabrin MJ, Brower SL, Coleman RL. Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study. Br J Cancer. 2014 Aug 26; 111(5):843-50. PMID: 25003664; PMCID: PMC4150278.
      Citations: 11     Fields:    Translation:Humans
    351. Abu-Rustum N, Chi D, Coleman RL, del Campo JM, Fotopoulou C, Frumovitz M, Gershenson DM, Gonzalez A, Jhingran A, Ledermann J, Mariani A, Mirza M, Oaknin A, Ramirez PT, Schmeler KM, Sood AK. Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer. Gynecol Oncol. 2014 Jul; 134(1):6-9. PMID: 24952408.
      Citations: 4     Fields:    Translation:Humans
    352. Monk BJ, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Karlan BY, Richardson G, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM, Poveda A, Ray-Coquard I, Provencher DM, Lhomm? C, Rinc?n DG, Redondo A. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014 Jul; 15(8):799-808. PMID: 24950985.
      Citations: 98     Fields:    Translation:HumansCTClinical Trials
    353. Sartor O, Coleman R, Nilsson S, Helle SI, O'Sullivan JM, Wiechno P, Logue J, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O'Bryan-Tear CG, Shan M, Parker C, Heinrich D, Foss? SD, Chodacki A, Widmark A, Johannessen DC, Bruland ?S. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014 Jun; 15(7):738-46. PMID: 24836273.
      Citations: 155     Fields:    Translation:HumansCTClinical Trials
    354. Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, Lu KH, Meyer LA. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer. Int J Gynecol Cancer. 2014 May; 24(4):713-7. PMID: 24651628; PMCID: PMC4039301.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    355. Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, Lutgendorf S, Sood AK. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol Ther. 2014 Jul; 15(7):919-29. PMID: 24755674; PMCID: PMC4100993.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    356. Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, Baggerly KA, Sood AK. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res. 2014 Jun 15; 20(12):3280-8. PMID: 24756370; PMCID: PMC4062703.
      Citations: 34     Fields:    Translation:Humans
    357. Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK. Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93. PMID: 24743243; PMCID: PMC4058356.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    358. Saxton JM, Scott EJ, Daley AJ, Woodroofe M, Mutrie N, Crank H, Powers HJ, Coleman RE. Effects of an exercise and hypocaloric healthy eating intervention on indices of psychological health status, hypothalamic-pituitary-adrenal axis regulation and immune function after early-stage breast cancer: a randomised controlled trial. Breast Cancer Res. 2014 Apr 14; 16(2):R39. PMID: 24731917; PMCID: PMC4052984.
      Citations: 33     Fields:    Translation:Humans
    359. Coleman R, Aksnes AK, Garcia C, Jerusalem G, Piccart M, Vobecky N, Thuresson M, Flamen P, Naume B. A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Res Treat. 2014 Jun; 145(2):411-8. PMID: 24728613; PMCID: PMC4025174.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    360. Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ, Anderson GL, Chambers SK, Markman M. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer. 2014 Jun; 50(9):1638-48. PMID: 24709487; PMCID: PMC4098779.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    361. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep. 2014 Apr 24; 7(2):488-500. PMID: 24703838; PMCID: PMC4038960.
      Citations: 26     Fields:    Translation:HumansCells
    362. Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, Matsuo K, Lee JS, Ram P, Coleman RL, Sood AK. Biologic effects of platelet-derived growth factor receptor a blockade in uterine cancer. Clin Cancer Res. 2014 May 15; 20(10):2740-50. PMID: 24634380; PMCID: PMC4024372.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    363. Nutter F, Holen I, Brown HK, Cross SS, Evans CA, Walker M, Coleman RE, Westbrook JA, Selby PJ, Brown JE, Ottewell PD. Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocr Relat Cancer. 2014 Apr; 21(2):327-41. PMID: 24413608.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    364. Graybill WS, Coleman RL. Vintafolide: a novel targeted agent for epithelial ovarian cancer. Future Oncol. 2014 Mar; 10(4):541-8. PMID: 24754586.
      Citations: 6     Fields:    Translation:HumansAnimals
    365. Takeuchi S, Lucchini M, Schmeler KM, Coleman RL, Gershenson DM, Munsell MF, Macapinlac HA, Ramirez PT. Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary. Gynecol Oncol. 2014 Apr; 133(1):100-4. PMID: 24534359; PMCID: PMC4000233.
      Citations: 7     Fields:    Translation:Humans
    366. Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanapprapasr D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, Kang Y, Jennings NB, Huang L, Deavers MT, Broaddus R, Coleman RL, Sood AK. Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. Clin Cancer Res. 2014 Apr 01; 20(7):1846-55. PMID: 24486585; PMCID: PMC3975695.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    367. Agarwal R, Alifrangis C, Everard J, Savage PM, Short D, Tidy J, Fisher RA, Sebire NJ, Harvey R, Hancock BW, Coleman RE, Seckl MJ. Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the U.K. experience, 1995-2010. J Reprod Med. 2014 Jan-Feb; 59(1-2):7-12. PMID: 24597279.
      Citations: 6     Fields:    Translation:Humans
    368. Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, Timmins H, Wheatley D, Grieve R, Griffiths G, Murray N. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol. 2014 Jan; 15(1):114-22. PMID: 24332514.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    369. Frumovitz M, Coleman RC, Soliman PT, Ramirez PT, Levenback CF. A case for caution in the pursuit of the sentinel node in women with endometrial carcinoma. Gynecol Oncol. 2014 Feb; 132(2):275-9. PMID: 24291694.
      Citations: 8     Fields:    Translation:Humans
    370. Thompson J, Coleman R, Colwell B, Freeman J, Greenfield D, Holmes K, Mathers N, Reed M. Preparing breast cancer patients for survivorship (PREP) - a pilot study of a patient-centred supportive group visit intervention. Eur J Oncol Nurs. 2014 Feb; 18(1):10-6. PMID: 24287045.
      Citations: 7     Fields:    Translation:Humans
    371. Herzog TJ, Armstrong DK, Brady MF, Coleman RL, Einstein MH, Monk BJ, Mannel RS, Thigpen JT, Umpierre SA, Villella JA, Alvarez RD. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol. 2014 Jan; 132(1):8-17. PMID: 24239753; PMCID: PMC4702266.
      Citations: 24     Fields:    Translation:Humans
    372. Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AK. Platelet-derived growth factor receptor alpha (PDGFRa) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol. 2014 Jan; 132(1):166-75. PMID: 24183729; PMCID: PMC3946949.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    373. Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2013 Dec 10; 31(35):4400-6. PMID: 24127448.
      Citations: 74     Fields:    Translation:HumansCTClinical Trials
    374. Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, Ivan C, Gallick GE, Baggerly KA, Hangauer DG, Coleman RL, Frumovitz M, Sood AK. Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6532-43. PMID: 24100628; PMCID: PMC3852199.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    375. Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Zhao C, Chia YL, Hoch U, Hannah AL, Perez EA, NKTR-102 Study Group, Awada A. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol. 2013 Nov; 14(12):1216-25. PMID: 24095299.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    376. Hadji P, Coleman R, Gnant M. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. Crit Rev Oncol Hematol. 2013 Aug; 87(2):101-11. PMID: 23838481.
      Citations: 23     Fields:    Translation:HumansAnimals
    377. Galic V, Coleman RL, Herzog TJ. Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways. Curr Cancer Drug Targets. 2013 Jul; 13(6):698-707. PMID: 23675882.
      Citations: 9     Fields:    Translation:HumansCells
    378. Rathbone EJ, Brown JE, Marshall HC, Collinson M, Liversedge V, Murden GA, Cameron D, Bell R, Spensley S, Agrawal R, Jyothirmayi R, Chakraborti P, Yuille F, Coleman RE. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). J Clin Oncol. 2013 Jul 20; 31(21):2685-91. PMID: 23796998.
      Citations: 17     Fields:    Translation:Humans
    379. Craig CD, Iglesias DA, Watkins J, Coleman RL, Kilgore L, Ramirez PT. Extensive cutaneous metastases of ovarian cancer after prolonged response to liposomal doxorubicin. Gynecol Oncol Case Rep. 2013; 5:64-6. PMID: 24371701; PMCID: PMC3862230.
      Citations: 1     
    380. Gartrell BA, Coleman RE, Fizazi K, Sternberg CN, Galsky MD, Miller K, Saad F. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-?B ligand inhibitors in patients with advanced prostate cancer. Eur Urol. 2014 Feb; 65(2):278-86. PMID: 23706567; PMCID: PMC4744484.
      Citations: 18     Fields:    Translation:HumansCells
    381. Young RJ, Coleman RE. Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug. Future Oncol. 2013 May; 9(5):633-43. PMID: 23647292.
      Citations: 13     Fields:    Translation:Humans
    382. Winter MC, Wilson C, Syddall SP, Cross SS, Evans A, Ingram CE, Jolley IJ, Hatton MQ, Freeman JV, Mori S, Holen I, Coleman RE. Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study. Clin Cancer Res. 2013 May 15; 19(10):2755-65. PMID: 23515409.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    383. Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol. 2013 Jun; 129(3):452-8. PMID: 23474348.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    384. Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM, Aft R, Tevaarwerk AJ, Swenson K, Lind P, Mauri D. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist. 2013; 18(4):353-61. PMID: 23404816; PMCID: PMC3639520.
      Citations: 28     Fields:    Translation:Humans
    385. Coleman RE, Lipton A, Costa L, Cook RJ, Lee KA, Brown JE, Terpos E, Major PP, Kohno N, Smith M, Body JJ, Saad F. Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials. J Bone Oncol. 2013 Jun; 2(2):70-6. PMID: 26909273; PMCID: PMC4723367.
      Citations: 15     
    386. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013 Apr; 10(4):211-24. PMID: 23381004; PMCID: PMC3786558.
      Citations: 230     Fields:    Translation:Humans
    387. Julius JM, Tanyi JL, Nogueras-Gonzalez GM, Watkins JL, Coleman RL, Wolf JK, Smith JA. Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer. Int J Gynecol Cancer. 2013 Feb; 23(2):348-54. PMID: 23295941; PMCID: PMC3899886.
      Citations: 3     Fields:    Translation:Humans
    388. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb; 14(2):134-40. PMID: 23261356; PMCID: PMC3627419.
      Citations: 131     Fields:    Translation:HumansCellsCTClinical Trials
    389. Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Rupin M, Vogel C, TRIO/BCIRG 001 investigators, Rodr?guez-Lescure A, Wilson V, Hou? V. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013 Jan; 14(1):72-80. PMID: 23246022.
      Citations: 86     Fields:    Translation:HumansCTClinical Trials
    390. Miyake TM, Sood AK, Coleman RL. Contemporary use of bevacizumab in ovarian cancer. Expert Opin Biol Ther. 2013 Feb; 13(2):283-94. PMID: 23190436; PMCID: PMC3799801.
      Citations: 8     Fields:    Translation:Humans
    391. Coleman RL, Ali S, Levenback CF, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ, Van Le L, Trimble CL. Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173. Gynecol Oncol. 2013 Feb; 128(2):155-9. PMID: 23201592; PMCID: PMC3638213.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    392. Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AK. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol. 2013 Mar; 128(3):506-11. PMID: 23200915; PMCID: PMC3645276.
      Citations: 14     Fields:    Translation:HumansCells
    393. Schmeler KM, Wilson GL, Cain K, Munsell MF, Ramirez PT, Soliman PT, Nick AM, Frumovitz M, Coleman RL, Kroll MH, Levenback CF. Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies. Gynecol Oncol. 2013 Feb; 128(2):204-8. PMID: 23200912; PMCID: PMC3826112.
      Citations: 16     Fields:    Translation:Humans
    394. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res. 2012 Nov 01; 18(21):5856-64. PMID: 23082003.
      Citations: 154     Fields:    Translation:HumansCells
    395. Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol. 2012 Nov 10; 30(32):4026-34. PMID: 23008289; PMCID: PMC3488272.
      Citations: 97     Fields:    Translation:HumansAnimalsCells
    396. Brown JE, Cook RJ, Lipton A, Coleman RE. Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients. Clin Cancer Res. 2012 Nov 15; 18(22):6348-55. PMID: 22952345.
      Citations: 32     Fields:    Translation:Humans
    397. Coleman RE. Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study. Curr Opin Support Palliat Care. 2012 Sep; 6(3):322-9. PMID: 22801464.
      Citations: 13     Fields:    Translation:Humans
    398. Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Dec; 127(3):538-43. PMID: 22922531; PMCID: PMC3568489.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    399. Revyakin A, Zhang Z, Coleman RA, Li Y, Inouye C, Lucas JK, Park SR, Chu S, Tjian R. Transcription initiation by human RNA polymerase II visualized at single-molecule resolution. Genes Dev. 2012 Aug 01; 26(15):1691-702. PMID: 22810624; PMCID: PMC3418587.
      Citations: 42     Fields:    Translation:HumansCells
    400. Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ, Van Le L, Trimble CL. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol. 2012 Nov 01; 30(31):3786-91. PMID: 22753905; PMCID: PMC3478573.
      Citations: 66     Fields:    Translation:HumansCTClinical Trials
    401. Coleman R, Gnant M, Morgan G, Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst. 2012 Jul 18; 104(14):1059-67. PMID: 22752060.
      Citations: 83     Fields:    Translation:Humans
    402. Kingdon SJ, Coleman RE, Ellis L, Hancock BW. Deaths from gestational trophoblastic neoplasia: any lessons to be learned? J Reprod Med. 2012 Jul-Aug; 57(7-8):293-6. PMID: 22838243.
      Citations: 1     Fields:    Translation:Humans
    403. Westin SN, Herzog TJ, Coleman RL. Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs. 2013 Feb; 31(1):213-29. PMID: 22661305; PMCID: PMC4103697.
      Citations: 13     Fields:    Translation:HumansCells
    404. Zand B, Coleman RL, Sood AK. Targeting angiogenesis in gynecologic cancers. Hematol Oncol Clin North Am. 2012 Jun; 26(3):543-63, viii. PMID: 22520979; PMCID: PMC3334841.
      Citations: 3     Fields:    Translation:Humans
    405. Berruti A, Cook R, Saad F, Buttigliero C, Lipton A, Tampellini M, Lee KA, Coleman RE, Smith MR. Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. Oncologist. 2012; 17(5):645-52. PMID: 22523198; PMCID: PMC3360904.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    406. Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC, Mills GB. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):47-53. PMID: 22487539; PMCID: PMC3738300.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    407. Nihira MA, Drake NL, Corton MM, Wai CY, Coleman RL, Quiroz LH. Reported cystoscopic experience correlates poorly with objective assessment of cystoscopic skills. Female Pelvic Med Reconstr Surg. 2012 Mar-Apr; 18(2):97-102. PMID: 22453320.
      Citations:    Fields:    Translation:Humans
    408. Annunziata CM, Kohn EC, LoRusso P, Houston ND, Coleman RL, Buzoianu M, Robbie G, Lechleider R. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs. 2013 Feb; 31(1):77-84. PMID: 22370972; PMCID: PMC3553417.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    409. Noguera IR, Sun CC, Broaddus RR, Branham D, Levenback CF, Ramirez PT, Sood AK, Coleman RL, Gershenson DM. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012 Jun; 125(3):640-5. PMID: 22387451.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    410. Milam MR, Java J, Walker JL, Metzinger DS, Parker LP, Coleman RL, Gynecologic Oncology Group. Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol. 2012 Feb; 119(2 Pt 1):286-92. PMID: 22270280; PMCID: PMC3266531.
      Citations: 36     Fields:    Translation:Humans
    411. Brown JE, Coleman RE. Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol. 2012 Jan 10; 9(2):110-8. PMID: 22231759.
      Citations: 31     Fields:    Translation:HumansCells
    412. Thanapprapasr D, Hu W, Sood AK, Coleman RL. Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer. Curr Pharm Des. 2012; 18(19):2713-9. PMID: 22390757; PMCID: PMC3740204.
      Citations: 7     Fields:    Translation:Humans
    413. Schmeler KM, Sood AK, Bell-McGuinn KM, Coleman RL, Frumovitz M, Sonoda Y, Ramirez PT, Gershenson DM, Barakat RR, Gardner GJ. Proceedings from the 9th International Conference on Ovarian Cancer. Gynecol Oncol. 2012 Apr; 125(1):5-7. PMID: 22210309; PMCID: PMC3746346.
      Citations:    Fields:    Translation:Humans
    414. Coleman RE. Bone cancer in 2011: Prevention and treatment of bone metastases. Nat Rev Clin Oncol. 2011 Dec 20; 9(2):76-8. PMID: 22182971.
      Citations: 37     Fields:    Translation:Humans
    415. Sood AK, Coleman RL, Ellis LM. Moving beyond anti-vascular endothelial growth factor therapy in ovarian cancer. J Clin Oncol. 2012 Feb 01; 30(4):345-7. PMID: 22184398.
      Citations: 7     Fields:    Translation:HumansAnimals
    416. Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, Coleman RE, Freedman OC, Jordan LB, Thompson AM. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev. 2012 Oct; 38(6):708-14. PMID: 22178456.
      Citations: 67     Fields:    Translation:Humans
    417. Julius JM, Gaikwad A, Lowry A, Lewis RE, Lozano RD, Dalrymple JL, Coleman RL, Smith JA. Defining the role of echinocandin catechol functional groups in the development of secondary hepatocellular carcinoma. J Antimicrob Chemother. 2012 Feb; 67(2):422-9. PMID: 22129592.
      Citations: 1     Fields:    Translation:HumansCells
    418. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C, Dami?o R, G?mez-Veiga F. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012 Jan 07; 379(9810):39-46. PMID: 22093187; PMCID: PMC3671878.
      Citations: 290     Fields:    Translation:HumansCTClinical Trials
    419. Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94. PMID: 22072418.
      Citations: 59     Fields:    Translation:Humans
    420. Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Paridaens R, van de Velde CJ, Morden J, Reise J, Cisar L, Menschik T, Coombes RC, Andersen J, L?nning PE. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol. 2012 Mar 01; 30(7):709-17. PMID: 22042946.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    421. Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, Schmeler KM, Iyer RB, Garcia ME, Miller DL, Jackson EF, Ng CS, Kundra V, Jaffe R, Sood AK. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol. 2011 Nov; 12(12):1109-17. PMID: 21992853; PMCID: PMC3444811.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    422. Ottewell PD, Brown HK, Jones M, Rogers TL, Cross SS, Brown NJ, Coleman RE, Holen I. Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice. Breast Cancer Res Treat. 2012 Jun; 133(2):523-36. PMID: 21956211.
      Citations: 9     Fields:    Translation:AnimalsCells
    423. Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein G, Sood AK. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst. 2011 Nov 02; 103(21):1596-612. PMID: 21957230; PMCID: PMC3206039.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    424. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R, AZURE Investigators. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011 Oct 13; 365(15):1396-405. PMID: 21995387.
      Citations: 191     Fields:    Translation:HumansCTClinical Trials
    425. Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res. 2011 Nov 01; 17(21):6840-6. PMID: 21890452; PMCID: PMC3207033.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    426. Alazzam M, Young T, Coleman R, Hancock B, Drew D, Wilson P, Tidy J. Predicting gestational trophoblastic neoplasia (GTN): is urine hCG the answer? Gynecol Oncol. 2011 Sep; 122(3):595-9. PMID: 21684585.
      Citations: 8     Fields:    Translation:Humans
    427. Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs. 2011 Jul 30; 71(11):1397-412. PMID: 21812505.
      Citations: 51     Fields:    Translation:Humans
    428. Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman RL, Sood AK. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res. 2011 Sep 15; 71(18):6030-9. PMID: 21795478; PMCID: PMC3174342.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    429. Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, Marty M, Coleman RE, Tubiana-Mathieu N, den Boer MO, Wardley A, Kilburn LS, Cooper D, Thomas MW, Reise JA, Wilkinson K, Hupperets P. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer. J Clin Oncol. 2011 Aug 20; 29(24):3247-54. PMID: 21768453.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    430. Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CN. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res. 2011 Sep 01; 17(17):5674-85. PMID: 21753153; PMCID: PMC3166981.
      Citations: 58     Fields:    Translation:HumansAnimalsCells
    431. Frederick PJ, Ramirez PT, McQuinn L, Milam MR, Weber DM, Coleman RL, Gershenson DM, Landen CN. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer. Int J Gynecol Cancer. 2011 Jul; 21(5):831-6. PMID: 21613957.
      Citations: 5     Fields:    Translation:Humans
    432. Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Jul; 122(1):111-5. PMID: 21497382; PMCID: PMC3104117.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    433. Armstrong DK, Coleman RL, Penson RT. Emerging therapeutic options for platinum-sensitive ovarian cancer patients. Clin Adv Hematol Oncol. 2011 Apr; 9(4 Suppl 5):1-16. PMID: 21558997.
      Citations:    Fields:    Translation:Humans
    434. Lacour RA, Euscher E, Atkinson EN, Sun CC, Ramirez PT, Coleman RL, Brown J, Gano JB, Burke TW, Ramondetta LM. A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. Int J Gynecol Cancer. 2011 Apr; 21(3):517-22. PMID: 21436700.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    435. Slomovitz BM, Worley MJ, Markman M, Coleman RL. Emerging therapeutics for primary peritoneal cancer. Expert Opin Emerg Drugs. 2011 Mar; 16(1):71-84. PMID: 21352070.
      Citations:    Fields:    Translation:Humans
    436. Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG, Lankes HA. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):303-8. PMID: 21329967; PMCID: PMC3081894.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    437. Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, Degeest K, Yamada SD, Waggoner S, Coleman RL, Walker JL, Mannel RS. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):264-8. PMID: 21277623; PMCID: PMC3081997.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    438. Harper P, Coleman RE, Lipton A, Costa L. Anticancer evidence for zoledronic acid across the cancer continuum. Crit Rev Oncol Hematol. 2011 Feb; 77 Suppl 1:S31-7. PMID: 21353179.
      Citations: 11     Fields:    Translation:Humans
    439. Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Stenning SP. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011 Mar 10; 29(8):957-62. PMID: 21282539.
      Citations: 54     Fields:    Translation:Humans
    440. Cheng X, Yang G, Schmeler KM, Coleman RL, Tu X, Liu J, Kavanagh JJ. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol. 2011 May 01; 121(2):323-7. PMID: 21277011.
      Citations: 23     Fields:    Translation:Humans
    441. Milam MR, Tao X, Coleman RL, Harrell R, Bassett R, Dos Reis R, Ramirez PT. Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2011 Jan; 21(1):66-71. PMID: 21178571.
      Citations: 4     Fields:    Translation:Humans
    442. Coleman R, Cook R, Hirsh V, Major P, Lipton A. Zoledronic acid use in cancer patients: more than just supportive care? Cancer. 2011 Jan 01; 117(1):11-23. PMID: 21235033.
      Citations: 20     Fields:    Translation:Humans
    443. Carroll AR, Coleman RL, Sood AK. Therapeutic advances in women's cancers. Front Biosci (Schol Ed). 2011 01 01; 3(1):82-97. PMID: 21196359; PMCID: PMC3199127.
      Citations: 1     Fields:    Translation:Humans
    444. Ito K, Tsubamoto H, Itani Y, Kuroboshi H, Fujita H, Nobunaga T, Coleman RL. A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer: a Kansai Clinical Oncology Group study (KCOG0015 trial). Gynecol Oncol. 2011 Feb; 120(2):193-7. PMID: 21075434.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    445. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2011 Jan; 11(1):59-67. PMID: 21160526; PMCID: PMC3199132.
      Citations: 269     Fields:    Translation:Humans
    446. Holen I, Coleman RE. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res. 2010; 12(6):214. PMID: 21176176; PMCID: PMC3046431.
      Citations: 31     Fields:    Translation:HumansAnimals
    447. Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth WA, Nugent E, Han LY, Landen CN, Nick AM, Stone RL, Coffman K, Bruckheimer E, Broaddus RR, Gershenson DM, Coleman RL, Sood AK. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2010 Dec 15; 10(12):1306-14. PMID: 20948320; PMCID: PMC3047089.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    448. Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer. 2011 May 01; 117(9):1928-34. PMID: 21509770; PMCID: PMC4286384.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    449. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9. PMID: 21472713; PMCID: PMC3062960.
      Citations: 79     Fields:    Translation:HumansCellsCTClinical Trials
    450. Brown J, Smith JA, Ramondetta LM, Sood AK, Ramirez PT, Coleman RL, Levenback CF, Munsell MF, Jung M, Wolf JK. Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer. 2010 Nov 01; 116(21):4973-9. PMID: 20665499; PMCID: PMC4210375.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    451. Gehlert S, Coleman R. Using community-based participatory research to ameliorate cancer disparities. Health Soc Work. 2010 Nov; 35(4):302-9. PMID: 21171537; PMCID: PMC3016944.
      Citations: 27     Fields:    Translation:Humans
    452. Nick AM, Schmeler KM, Frumovitz MM, Soliman PT, Spannuth WA, Burzawa JK, Coleman RL, Wei C, Dos Reis R, Ramirez PT. Risk of thromboembolic disease in patients undergoing laparoscopic gynecologic surgery. Obstet Gynecol. 2010 Oct; 116(4):956-961. PMID: 20859161.
      Citations: 10     Fields:    Translation:Humans
    453. Trimble EL, Birrer MJ, Hoskins WJ, Marth C, Petryshyn R, Quinn M, Thomas GM, Kitchener HC, Gynecologic Cancer Intergroup/National Cancer Institute Writing Committee, Aghajanian C, Alberts DS, Armstrong D, Brown J, Coleman RL, Colombo N, Eisenhauer E, Friedlander M, Fujiwara K, Hunsberger S, Kaye S, Ledermann JA, Lee S, Look K, Mannel R, McNeish IA, Minasian L, Oza A, Paul J, Poveda A, Pujade-Lauraine E, Schoenfeldt M, Swart AM, von Gruenigen V, Wenzel L. Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. Int J Gynecol Cancer. 2010 Oct; 20(7):1290-8. PMID: 21151709; PMCID: PMC2998994.
      Citations: 4     Fields: